**CURRICULUM VITAE**

**Yisheng Li, Ph.D.**

**PRESENT TITLE AND AFFILIATION**

**Primary Appointment**

Professor, Department of Biostatistics, VP, Research, The University of Texas MD Anderson Cancer Center, Houston, TX

**Dual/Joint/Adjunct Appointment**

Regular Member, Quantitative Sciences Program, The University of Texas Graduate School of Biomedical Science, Houston, TX

Adjunct Professor, Department of Statistics, Rice University, Houston, TX

Adjunct Professor, Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX

**CITIZENSHIP**

United States

**OFFICE ADDRESS**

The University of Texas MD Anderson Cancer Center

7007 Bertner Ave

Unit Number: 1689

Houston, TX 77030

Room Number: 1MC12.3217

Phone: (713) 563-4267

Fax: (713) 563-4243

Email: ysli@mdanderson.org

**EDUCATION**

**Degree-Granting Education**

Peking University, Beijing, China, BS, 1991, Probability & Statistics

Sun Yat-sen University, Guangzhou, China, MS, 1994, Probability & Statistics

University of Toledo, Toledo, OH, MS, 1998, Statistics

University of Michigan, Ann Arbor, MI, PHD, 2003, Biostatistics

**Postgraduate Training**

N/A

**CREDENTIALS**

**Board Certification**

N/A

**Licensures**

**Active**

N/A

**Inactive**

N/A

**EXPERIENCE/SERVICE**

**Academic Appointments**

Assistant Professor, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2004-9/2010

Visiting Assistant Professor, Department of Statistics, Rice University, Houston, TX, 1/2008-6/2008

Visiting Assistant Professor, Department of Statistics, Rice University, Houston, TX, 1/2010-5/2010

Associate Professor, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2010-8/2020

Regular Member, Quantitative Sciences Program, The University of Texas Graduate School of Biomedical Science, Houston, TX, 9/2018-present

Adjunct Associate Professor, Department of Statistics, Rice University, Houston, TX, 7/2019-6/2022

Professor, Department of Biostatistics, VP, Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2020-present

Adjunct Professor, Department of Statistics, Rice University, Houston, TX, 7/2022-present

Adjunct Professor, Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 11/2022-present

**Administrative Appointments/Responsibilities**

N/A

**Other Appointments/Responsibilities**

Research Assistant, University of Michigan, Ann Arbor, MI, 9/1999-5/2002

Research Assistant, University of Michigan, Ann Arbor, MI, 5/2003-10/2003

**Endowed Positions**

N/A

**Consultantships**

Parke-Davis Pharmaceutical Research (Pfizer Inc.), Ann Arbor, MI, Research Assistant, 9/1998-4/1999

Wyeth Research, Collegeville, PA, Summer Intern, 6/2002-12/2002

Boron, Lepore & Associates, Cardinal Health, San Diego, CA, Consultant, 12/2002

**Military or Other Governmental Service**

N/A

**Institutional Committee Activities**

Psychosocial, Behavioral and Health Services Research Committee (PBHSRC), Member, 2006-2009

Institutional Review Board (IRB) 5, Associate Member, 5/2008-8/2010

Institutional Animal Care and Use Committee (IACUC), Ex-Officio Member, 8/2010-present

Institutional Review Board (IRB) 5, Member, 9/2010-8/2022

Data and Safety Monitoring Board (DSMB), Member, 11/2017-8/2022

Institutional Review Board (IRB) 3, Member, 9/2022-present

**HONORS AND AWARDS**

Merit-award recipient, Peking University, Department of Probability and Statistics, 1988

Merit-award (first prize) recipient, Sun Yat-sen University, Department of Mathematics, 1992

Title winner of "Outstanding Graduate Student," Sun Yat-sen University, Department of Mathematics, 1994

Fellowship, University of Michigan, Department of Biostatistics, 2003

Travel Award, Current and Future Trends in Nonparametrics conference, Columbia, SC, 2007

Early Career Researcher Travel Award, 9th World Meeting of the International Society for Bayesian Analysis (ISBA), Hamilton Island, Australia, ISBA, 2008

Acceptance into Cambridge Who's Who among Executives, Professionals and Entrepreneurs, Cambridge Who's Who, 2009

Best Poster Presentation, The International Workshop on Objective Bayes Methodology, Philadelphia, PA, The International Society for Bayesian Analysis, 2009

Young Researcher Travel Award, The 11th Annual Winter Workshop on Semiparametric Methodology, Gainesville, FL, 2009

Ranked #3 for a few months in the 10 most accessed Biometrics papers, The International Biometric Society, 2010-2011

Acceptance into Marquis Who's Who in the World, Marquis Who's Who, 2017

PhD student Chao Yang's paper selected as one of three finalists of Thomas Chalmers Award at the 44th Society of Clinical Trials (SCT) Meeting, Society of Clinical Trials, 2023

**RESEARCH**

**Grants and Contracts**

**Funded**

Co-Investigator, 5%, Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC), 5U01DK108328-08, NIH/NIDDK, PI - Ying Yuan, 9/28/2015-6/30/2025, $13,995,007 ($978,288/year)

Biostatistician, Cancer Center Support Grant (CCSG) - Biostatistics Resource Group (BRG), 5P30CA016672-47, NIH/NCI, PI - Draetta, Giulio, 7/1/2019-6/30/2026, $55,148,350 ($3,040,976/year)

Co-Director of Biostatistics and Bioinformatics Core, 20%, The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma, 5P50CA217674-04, NIH/NCI, PI - Laura Beretta, 9/25/2019-8/31/2024, $11,483,235 ($1,462,928/year)

Co-Investigator, 1%, Optimizing Treatments for Chemotherapy-Induced Peripheral Neuropathy, 133706-RSG-19-155-01-PCSM, Rising Tide Foundation for Clinical Cancer Research/American Cancer Society, PI - Sarah Prinsloo, 1/1/2020-8/31/2024, $738,000 ($163,747/year)

Co-Investigator, 1%, Comparative Modeling of Precision Breast Cancer Control Across the Translational Continuum, 5U01CA253911-02, NIH/NCI subaward via University of Wisconsin Madison, PI - Amy Trentham-Dietz/ Xuelin Huang, 9/1/2020-8/31/2025, $1,134,000 ($55,079/year)

Co-Investigator, Improving Health Utilization and Quality of Life in Head and Neck Cancer Patients Undergoing Chemoradiation and their Family Caregivers, 5R01CA247307-03, NIH/NCI, PI - Kathrin Milbury, 9/15/2020-6/30/2026, $2,785,036 ($171,915/year)

Biostatistician, Biofield Therapy in Oncology, LS2020-00058378 / 2020-1210, Emerald Gate Charitable Trust, PI - Lorenzo Cohen, 9/23/2020-5/31/2025, $727,000

Co-mentor, Social determinants of sleep and obesity: disparities in African Americans, 1K99MD015296-01A1, NIH/NIMHD, PI - Ivan Wu, 4/1/2021-3/31/2026, $657,005 ($97,785/year)

Co-Investigator, 1%, Peer-Based Approaches to Enhance Physical Activity in Dyads of Inactive Women, 5R01HL155310-02, NIH/NHLBI, PI - Larkin Strong, 5/1/2021-4/30/2026, $3,729,354 ($511,321/year)

Co-Investigator, 2%, Health Benefits of Writing Therapy among Chinese Breast Cancer Survivors, FP00007804\_Res2, American Cancer Society (ACS), PI - Qian Lu, 7/1/2021-6/30/2026, $2,362,212 ($393,045/year)

Co-Investigator, 8%, Writing to Heal: A Culturally Based Brief Expressive Writing Intervention for Chinese Immigrant Breast Cancer Survivors, 5R01CA248213-02, NIH/NCI, PI - Qian Lu, 7/1/2021-6/30/2026, $3,037,173 ($496,751/year)

Co-Investigator, 12%, Promoting HPV Vaccination among Young Adults in Texas, 5R01CA248216-02, NIH/NCI, PI - Qian Lu, 8/1/2021-7/31/2026, $4,047,152 ($809,815/year)

Co-Investigator, 5%, Parenting Intervention for Caregivers who Parent a Young Child while Caring for a Spouse with an Incurable Cancer, 5R21CA256694-02, NIH/NCI, PI - Kathrin Milbury, 9/23/2021-8/31/2024, $459,648 ($209,309/year)

Co-Investigator, Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell Therapy, 1R01CA266714-01A1, NIH/NCI, PI - Cassian Yee, 7/20/2022-6/30/2027, $2,489,990 ($497,998/year)

Co-Investigator, 5%, Simulation-Based Caregiving Skills Training for Family Members of High Grade Glioma Patients, 1R21CA273782-01, NIH/NCI, PI - Kathrin Milbury, 9/1/2022-8/31/2024, $292,920 ($133,960/year)

Co-Investigator, 6%, Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults, 1R01AT012375-01, NIH/NCCIH, PI - Scherezade Mama, 2/24/2023-3/31/2026, $1,695,651 ($349,856/year)

Co-Investigator, 1%, Randomized controlled trial to test feasibility of a culturally adapted meditation-based support intervention for Black patients dealing with advanced cancer, 1R34AT012360-01, NIH/NCCIH, PI - Dalnim Cho, 4/1/2023-3/31/2026, $729,000 ($150,000/year)

Co-Investigator, 2%, Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery, 1R01CA272565-01A1, NIH/NCI, PI - Lorenzo Cohen, 4/1/2023-3/31/2028, $3,937,602 ($495,583/year)

Co-Investigator, 5%, Harmony & Health: A culturally adapted mind-body intervention to reduce sitting time and improve psychosocial wellbeing in Black adults, #TBA, American Cancer Society (ACS), PI - Scherezade Mama, 7/1/2023-6/30/2027, $791,999 ($164,999/year)

Co-Investigator, 5%, Psycho-Spiritual Management for Patients with Advanced Cancer and their Family Caregivers, 1R01CA276035-01A1, NIH/NCI, PI - Kathrin Milbury, 7/1/2023-6/30/2028, $4,027,720 ($591,244/year)

**Pending**

Co-Mentor, A Virtual, Group-Based Expressive Writing Intervention for Adolescent and Young Adult Cancer Survivors, 1K99CA286800-01, NIH/NCI, PI - Eunju Choi, 12/1/2023-11/30/2028, $1,115,748 ($1,095,100/year)

Co-Investigator, 1%, Biobehavioral effects of Yoga for cancer patients undergoing Hematopoietic Stem Cell Transplantation, #TBA, GABRIELLES ANGEL FDN FOR CANCER RESEARCH, PI - Santhosshi Narayanan, 1/1/2024-12/31/2026, $224,996 ($68,181/year)

Co-Investigator, 3%, Feasibility of Conducting a Randomized Controlled Trial of Yoga for Patients Undergoing Hematopoietic Stem Cell Transplantation, 1R21CA292193-01, NIH/NCI, PI - Lorenzo Cohen, 7/1/2024-6/30/2026, $445,500 ($150,000/year)

Co-Mentor, A Virtual, Group-Based, Expressive Writing Intervention for Survivors of Adolescent and Young Adult Cancer, #TBA, NIH/NCI, PI - Eunju Choi, 7/1/2024-6/30/2029, $1,084,860 ($127,714/year)

Co-Investigator, 2%, Pain Therapeutics Unveiled: Unraveling Biomarker Signatures for Clinical Trial Advancement, #TBA, NIH/NCI, PI - Sarah Prinsloo, 7/1/2024-6/30/2029, $5,992,757 ($544,057/year)

Co-Investigator, 5%, Dyadic yoga Program for Patients with Lung Cancer Undergoing Radiotherapy and their Family Caregivers, 4R37CA231522-07, NIH/NCI, PI - Kathrin Milbury, 8/1/2024-7/31/2025, $238,103 ($385,070/year)

Co-Investigator, 2%, Decoding Molecular Links of snoRNAs in Racial Disparities of NAFLD, GRANT14048363, NIH/NCI, PI - Chunru Lin, 8/1/2024-7/31/2026, $490,499 ($149,999/year)

Co-Investigator, 1%, NF230020: Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins, HT9425-23-NFRP-IIRA, Department of Defense (DOD), PI - Keila Torres, 8/1/2024-7/31/2027, $735,799 ($172,195/year)

Principal Investigator, 10%, Biostatistics and Bioinformatics, RP240440, Cancer Prevention & Research Institute of Texas (CPRIT), 8/31/2024-8/30/2028, $453,368 ($104,894/year)

Core Leader, 10%, Pediatric Bone Sarcoma (PBS) centric target and immune therapy discovery, #TBA, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Richard Gorlick, 8/31/2024-8/30/2028, $4,498,688 ($967,582/year)

Statistician, Multi-Disciplinary Approach to Treatment of Trismus (M-DATT), PAR-21-084, NIH/NCI, PI - Richard Cardoso, 9/1/2024-8/31/2026, $162,000 ($100,000/year)

Co-Investigator, 10%, Virtual Joy Luck Academy: A Culturally Centered Digital Intervention for Chinese Immigrant Breast Cancer Survivors, #TBA, NIH/NCI, PI - Qian Lu, 9/1/2024-8/31/2029, $4,991,340 ($671,915/year)

Administrative Core Co-Leader, 3%, Novel Mitochondrial Mechanisms in AML, #TBD, Leukemia and Lymphoma Society, PI - Michael Andreeff, 10/1/2024-9/30/2029, $4,882,471 ($830,020/year)

Co-Core Leader, 3%, Targeting Mitochondrial Homeostatsis in AML, #TBA, Leukemia & Lymphoma Society, PI - Michael Andreeff, 10/1/2024-9/30/2029, $4,882,465 ($935,160/year)

Co-Investigator, 5%, Magnesium-rich dietary intervention to prevent hypomagnesemia in ovarian cancer patients undergoing platinum-based chemotherapy, #TBA, NIH/NCI, PI - Lorenzo Cohen, 12/1/2024-11/30/2026, $449,625 ($125,000/year)

Co-Investigator, 5%, Dyadic-Focused Lifestyle Intervention for Black Prostate Cancer Survivors and Their Spouses: A Comparative Analysis, #TBA, NIH/NCI, PI - Dalnim Cho, 12/1/2024-11/30/2029, $4,020,162 ($486,918/year)

Co-Investigator, 5%, Exercise for Cancer Immune Interception in Lynch Syndrome Patients, GRANT14117266, NIH/NCI, PI - Eduardo Vilar Sanchez, 12/1/2024-11/30/2029, $5,944,170 ($947,214/year)

Co-Investigator, 3%, Together stronger: A couple-focused lifestyle intervention for Black prostate cancer survivors and their spouses, #TBA, American Cancer Society (ACS), PI - Dalnim Cho, 1/1/2025-12/31/2028, $945,213 ($214,999/year)

Core B: Biostats Core Co-Director, 10%, The University of Texas M.D. Anderson Cancer Center SPORE in Hepatocellular Carcinoma, #TBA, NIH/NCI, PI - Ahmed Kaseb, 6/1/2025-5/31/2030, $12,077,112 ($1,524,406/year)

**Other**

Co-Investigator, 1%, Mobile-Health Delivery of a Comprehensive Lifestyle Intervention for Overweight Women with Breast Cancer: Mechanisms and Biobehavioral Outcomes, Withdrawn, 1R21CA231507-01, NIH/NCI, PI - Lorenzo Cohen, 7/1/2018-6/30/2020, $275,000 ($137,500/year)

Collaborator, Optimizing Neurofeedback to Treat CIPN, ACS and Rising Tide Projects have been combined (Dr. Li is aware) – Per Shara Obi on 1/12/21 Dr. Li's effort/salary support will be on PID11200 (ACS) instead of PID11124 (Rising Tide)., CCR-19-200, Rising Tide Foundation for Clinical Cancer Research/American Cancer Society, PI - Prinsloo, 11/1/2019-10/31/2023, $126,482 ($537,324/year)

**Completed**

Co-Investigator, 20%, Race/Ethnicity and the Process of Smoking Cessation, 5 R01 DA014818 05, NIH/NIDA, PI - David W. Wetter, 9/30/2001-8/31/2007, $1,356,825 ($271,365/year)

Co-Investigator, 10%, Treatment of Nicotine Dependence Among African Americans, 5 R01 CA094826 05, NIH/NCI, PI - David W. Wetter, 9/30/2001-8/31/2007, $1,598,652 ($319,730/year)

Co-Investigator, 10%, Smoking relapse prevention among postpartum women, 5 R01 CA089350 06, NIH/NCI, PI - David W. Wetter, 2/1/2002-1/31/2009, $2,312,345 ($385,391/year)

Co-Investigator, A Sexual Counseling Intervention for Prostate Cancer Survivors, TURSG 02 189 01 PBP 04, American Cancer Society (ACS), PI - Leslie Schover, 7/1/2002-6/30/2008, $1,104,840 ($276,210/year)

Core Leader, Project EXPORT - A Center of Excellence (PEACE) Shared Resource Core (PC-C), 5 P60 MD000503 09, NIH/NCMHD, PI - Lovell Jones, 9/30/2003-4/30/2012, $143,009 ($43,322/year)

Co-Investigator, Pharmacogenetics, emotional reactivity and smoking cessation, 5 R01 DA017073 05, NIH/NIDA, PI - Paul M. Cinciripini, 7/15/2004-4/30/2011, $2,077,114 ($392,217/year)

Co-Investigator, 10%, Health communications and risk processing among smokers, 5 K01 DP000086 03, NIH/NCCDPHP, PI - Jennifer Irvin Vidrine, 9/30/2004-9/29/2008, $896,685 ($298,095/year)

Investigator, 6%, Group therapy for nicotine dependence, 5 R01 DA018875 05, NIH/NIDA, PI - David W. Wetter, 9/30/2004-8/31/2009, $1,900,433 ($380,087/year)

Co-Investigator, 5%, Interactive Media on Banking Sperm before Cancer Therapy, 7 R44 CA088088 04, NIH/NCI, PI - Paul Martinetti, 9/1/2005-8/31/2006, $411,735 ($147,424/year)

Investigator, Cognitive processes in smoking cessation, 7 R01 DA020436 04, NIH/NIDA, PI - Paul Cinciripini, 9/30/2005-8/31/2009, $949,014 ($237,254/year)

Statistician, 5%, Weight gain prevention for breast cancer survivors, 03, Lance Armstrong Foundation, PI - Karen M. Basen-Engquist, 1/1/2006-12/31/2008, $225,328 ($75,109/year)

Co-Investigator, 20%, An innovative telephone intervention for HIV+ smokers, 5 R01 CA097893 05, NIH/NCI, PI - Ellen R. Gritz, 2/1/2006-6/7/2010, $1,620,929 ($329,150/year)

Investigator, 10%, Smoking cessation intervention for depressed smokers: treatment development, 5 R01 MH076776 03, NIH/NIMH, PI - Janice Blalock, 9/12/2006-7/31/2009, $661,950 ($220,650/year)

Investigator, 3%, Interactive CD-ROM on cancer genetics for Hispanics, 5 R01 HG003844 03, NIH/NHGRI, PI - Susan K. Peterson, 9/15/2006-8/31/2009, $1,002,258 ($334,086/year)

Co-Investigator, 10%, Literacy and smoking risk communications, 5 R01 CA125413 03, NIH/NCI, PI - Jennifer Irvin Vidrine, 4/1/2007-2/28/2011, $570,000 ($190,000/year)

Co-Mentor, The effects of neighborhood characteristics on smoking cessation, 5 K01 DP001120 03, NIH/NCCDPHP, PI - Lorraine R. Reitzel, 8/31/2007-1/31/2011, $416,667 ($138,889/year)

Co-Investigator, 5%, Social Cognitive Theory and PA after Endometrial Cancer, 5 R01 CA109919 05, NIH/NCI, PI - Karen M. Basen-Engquist, 9/1/2007-8/31/2008, $289,728 ($289,728/year)

Co-mentor, M.D. Anderson Education Program in Cancer Prevention, 3 R25 CA057730 19S2, NIH/NCI, PI - Shine Chang, 9/14/2007-8/31/2012, $6,258,135 ($1,250,774/year)

Investigator, 5%, Ecological Monetary Assessment of Smoking Cessation in Spanish-Speaking Smokers, 1 K07 CA121037 01A2, NIH/NCI, PI - Carlos A. Mazas, 6/16/2008-5/31/2009, $114,280 ($114,280/year)

Co-Investigator, 1%, The influence of HIV disease events/stages on smoking attitudes and behaviors, 5 R01 CA132636 05, NIH/NCI, PI - Damon J. Vidrine, 7/1/2008-5/31/2014, $830,000 ($182,269/year)

Co-Investigator, 4%, Peer-support motivational interviewing PA intervention for African American women, 5 R21 CA134961 02, NIH/NCI, PI - Lorna H. McNeill, 9/1/2008-8/31/2011, $272,106 ($124,817/year)

Co-Investigator, 5%, Dissemination of a Smoking Quitline to the Underserved, 5 R18 DP001570 03, CDC/NCCDPHP, PI - Jennifer Irvin Vidrine, 9/1/2008-8/31/2012, $987,384 ($327,058/year)

Statistician, Efficacy of cancer support programs: a social comparison theory analysis, 5 R21 CA126854 02, NIH/NCI, PI - Cindy L. Carmack-Taylor, 9/15/2008-8/31/2011, $247,500 ($112,500/year)

Co-Investigator, UPRCCC/MDACC: Partners for Excellence in Cancer Research (PC-D), 5 U54 CA096300 08, NIH/NCI, PI - Raymond Dubois, 9/29/2008-8/30/2010, $130,103 ($20,165/year)

Statistician, 1%, Take Heart: Exercise & Diet Intervention for Heart Failure in Cancer Survivors, 5 R21 CA135016 02, NIH/NCI, PI - Karen Basen-Engquist, 3/13/2009-2/28/2012, $242,000 ($132,000/year)

Co-Investigator, Social contextual and environmental predictors of PA in sedentary minority adults, 5 R01 NR011453 05, NIH/NINR, PI - Lorna Haughton McNeill, 7/22/2009-12/30/2014, $2,178,362 ($407,193/year)

Co-Investigator, 1%, Intensive Smoking Cessation Intervention for Head and Neck Cancer Patients, 5 R01 CA120153 04, NIH/NCI, PI - Janice Blalock, 8/1/2009-10/31/2013, $622,500 ($36,383/year)

Co-Investigator, 8%, Reducing Tobacco Related Health Disparities, 5 R01 CA141613 04, NIH/NCI, PI - David W. Wetter, 9/1/2009-8/31/2014, $2,117,995 ($396,124/year)

Mentee, 20%, An Academic-Industry Dream Team Capitalizing on the Phosphatidylinositide 3 Kinase (PI3K) Pathway as a Target in Women's Cancers, SU2C-AACR-DT0209 02, AACR (Subcontract from Beth Israel Deaconess Medical Center), PI - Lewis C. Cantley, 11/1/2009-10/31/2013, $468,545 ($425,950/year)

Statistician, Oncologist-Assisted Home Exercise Program for Advanced Colon Cancer Patients, 5 R21 CA137333 02, NIH/NCI, PI - Karen Basen-Engquist, 12/1/2009-11/30/2011, $242,000 ($132,000/year)

Co-Investigator, 5%, Yoga for women with breast cancer undergoing radiotherapy, 5 R01CA138800-04, NIH/NCI, PI - Lorenzo Cohen, 4/1/2010-9/30/2017, $459,108 ($76,518/year)

Co-Investigator, 5%, Reducing Cancer Disparities Among Latinos in Texas (Research Core), 5 U54 CA153505 02, NIH/NCI, PI - David Wetter, 9/1/2010-8/31/2013, $1,028,945 ($204,490/year)

Co-Investigator, Comparative Modeling: Informing Breast Cancer Control Practice & Policy, 5 U01 CA152958 05, NIH/NCI (Subcontract from Georgetown University) CISNET, PI - Jeanne Susan Mandelblatt, 9/1/2010-8/31/2015 ($82,423/year)

Co-Investigator, 7%, Placebo Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia, 5 R01CA148707-04, NIH/NCI, PI - Lorenzo Cohen, 2/15/2011-1/31/2015, $2,284,300 ($450,522/year)

Co-Investigator, 5%, Application of Multi-modal Professional Education Platform to Facilitate Physician Tobacco Counseling for Smokers, PP110026-02, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Ludmila Cofta-Woerpel, 3/1/2011-8/28/2013, $299,947 ($299,947/year)

Co-Investigator, 10%, An evidence-based smoking cessation program for underserved persons living with HIV/AIDS, 172100-30-111870-46, Centers for Medicare and Medicaid Services (CMS), PI - Prokhorov, 6/15/2013-8/31/2016, $1,423,028 ($390,312/year)

Co-Investigator, 1%, A Pilot Study of Oncology Massage to Treat Chemotherapy-Induced Peripheral Neuropathy, MDACC Institutional Research Grant (IRG), PI - Gabriel Lopez, 12/12/2013-11/5/2016, $49,772 ($25,936/year)

Co-Investigator, 10%, Smoking Cessation for Cervical Cancer Survivors in a Safety Net Healthcare System, 1 R01 CA172786 01A1, NIH/NCI, PI - Jennifer Irvin Vidrine, 5/12/2014-4/30/2016, $1,713,814 ($371,805/year)

Co-Investigator, 10%, Modeling the impact of targeted therapy based on Breast Cancer Subtypes, 5U01CA187945-05, NCI (Subaward from University of California San Francisco), PI - Laura Esserman / Donald Berry, 9/18/2014-8/31/2019, $245,978 ($66,875/year)

Co-Investigator, 1%, Food Deserts in Houston? Increasing Fruit and Vegetable Consumption to Reduce Cancer Risk, DFI Seed Funding Research Program, UTMDACC Duncan Family Institute Seed Funding Research Program, PI - Lorna McNeill, 11/1/2014-10/31/2016, $99,170 ($49,585/year)

Collaborator, 5%, Comprehensive Integrative Oncology Clinical Trial, 13055845, Gateway for Cancer Research, PI - Lorenzo Cohen, 4/1/2015-12/31/2017

Co-Investigator, 10%, Smoking Cessation for Cervical Cancer Survivors in a Safety Net Healthcare System, 1-R01-CA172786-01A1, NIH (Subcontract from University of Oklahoma Health Sciences Center), PI - Lorna McNeill (Subcontract PI), 5/12/2015-4/30/2016 ($105,368/year)

Co-Investigator, 18%, Revising AJCC TNM Breast Cancer Staging: Analyzing National Datasets, 15122133, Breast Cancer Foundation, PI - Gabriel Hortobagyi (contact) / Donald Berry, 6/1/2015-5/31/2018, $118,385 ($118,385/year)

Co-Investigator, 2%, Couple-based meditation program for lung cancer patients and partners, PEP-15-055-01-PCSM, American Cancer Society (ACS), PI - Kathrin Milbury, 7/1/2015-6/30/2018, $142,114 ($59,414/year)

Co-Investigator, 10%, Project Heart: Biobehavioral effects on Cardiovascular Risk for Bereaved Spouses, 1 R01 HL127260-01, Subaward from Rice University /NHLBI, PI - Christopher Fagundes, 8/1/2015-8/31/2016, $2,525,042 ($489,926/year)

Co-Investigator, 10%, Pilot Cancer Intervention and Surveillance Modeling Network - BOLD Task Force Supplement, U01 CA152958, Subaward from Georgetown University (NCI), PI - Jeanne Mandelblatt, 9/1/2015-8/31/2016, $93,215 ($93,215/year)

Statistician, 5%, Servan Schrieber Cohen, 710177-80-107891, MDACC - Servan Schrieber Cohen, PI - Lorenzo Cohen, 9/1/2015-8/31/2016, $7,880 ($7,880/year)

Co-Investigator, 1%, Using telemonitoring to optimize the mobility of cancer survivors with skeletal metastases after surgery to preserve limb function, 2017-00053607-Y1, Cancer Survivorship Research Seed Money, PI - Robert Satcher, 9/1/2015-8/31/2017, $50,000 ($50,000/year)

Co-Investigator, Comparative Modeling: Informing Breast Cancer Control Practice and Policy, 5U01CA199218-05, NIH/NCI (Subaward from Georgetown University Medical Center), PI - Jeanne Mandelblatt, 9/1/2015-8/31/2020, $7,398,255 ($1,479,651/year)

Co-Investigator, 5%, Couple-based meditation program for patients with metastatic lung cancer and their partners, 5R21CA191711-02, NIH/NCI, PI - Kathrin Milbury, 12/28/2015-11/30/2017, $285,006 ($155,003/year)

Co-Investigator, 5%, Randomized-controlled trial of acupuncture for post-mastectomy pain syndrome, 51973, Gateway for Cancer Research, PI - Mary Kay Garcia, 7/1/2016-6/30/2018, $503,668 ($164,177/year)

Collaborator, 5%, Examination of HJC0152, a putative modulator of glucose and energy metabolism, for mammary cancer prevention, HHSN261201500018I, NIH/NCI PREVENT Cancer Program, PI - Qiang Shen, 8/1/2016-1/31/2019, $250,644 ($167,096/year)

Co-Investigator, 1%, Repetitive Transcranial Magnetic Stimulation to Treat Oxaliplatin-Induced Neuropathy in Colorectal Cancer Patients, 2017-00053890-Y1, IRG, PI - Sarah Prinsloo, 7/1/2017-6/30/2020, $150,000 ($75,000/year)

Co-Investigator, 5%, A Peer and Family-based Approach to Obesity in African American Families, RSG-17-158-01, American Cancer Society (ACS), PI - Lorna McNeill, 1/1/2018-6/30/2023, $1,737,305 ($376,637/year)

Co-Investigator, 3%, Yoga Intervention for Family Caregivers of Patients with Brain Tumors, 5R21CA218309-03, NIH/NCI, PI - Kathrin Milbury, 1/11/2018-12/31/2020, $405,072 ($108,750/year)

Collaborator, 5%, Chemoprevention of Breast Cancer by Targeting Glucose Metabolism with HJC0152, 5R01CA226001-02, NIH/NCI, PI - Qiang Shen, 4/1/2018-3/31/2023, $2,138,999 ($351,122/year)

Co-Investigator, 3%, Understanding barriers and decreasing the time to chemotherapy in a vulnerable population: Pilot study of a targeted intervention, FP00004259, Conquer Cancer Foundation of the American Society of Clinical Oncology, PI - Chavez Mac Gregor, 7/1/2018-12/31/2022, $416,443 ($137,589/year)

Co-Investigator, 5%, Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer, 5R01CA231150-02, NIH/NCI, PI - Qiang Shen, 7/1/2018-6/30/2023, $2,209,248 ($440,690/year)

Co-Investigator, 5%, Dyadic yoga Program for Patients with Lung Cancer Undergoing Radiotherapy and their Family Caregivers, 5R37CA231522-06, NIH/NCI, PI - Kathrin Milbury, 8/9/2018-7/31/2024, $1,775,095 ($250,000/year)

Co-Investigator, 5%, A family-based approach to reducing obesity risk among African American families, 5R21NR017425-02, NIH/NINR PREVENT Cancer Program, PI - Lorna McNeill, 8/15/2018-7/31/2021, $720,000 ($125,000/year)

Co-Investigator, 5%, Yoga Program for Couples Coping with Lung Cancer, 132956-RSG-18-175-01-PCSM, American Cancer Society (ACS), PI - Kathrin Milbury, 1/1/2019-12/31/2023, $396,000 ($164,910/year)

Co-Investigator, 2%, Mind-body Medicine for Adolescents and Young Adults (AYA) Coping with Hodgkin Lymphoma, 115, Gabrielles Angel FDN For Cancer Research, PI - Kathrin Milbury, 8/27/2019-8/26/2023, $225,000 ($68,177/year)

Co-Investigator, 2%, A social media game to increase physical activity among older adult women, 5R01AG064092-04, NIH/NIA subaward via UTMB-Galveston, PI - Elizabeth Lyons, 9/30/2019-5/31/2024, $1,993,270 ($27,614/year)

Co-Investigator, 1%, Reducing breast cancer risk through modifying body composition and decreasing inflammation in normal weight women, 5R21CA239079-02, NIH/NCI, PI - Karen Basen-Engquist, 1/14/2020-12/31/2023, $457,326 ($133,512/year)

Co-Investigator, 2%, One Plus One Can Be Greater than Two: Ecological Momentary Assessment for Black Prostate cancer Survivors and Partners, 5R21CA245687-02, NIH/NCI, PI - Dalnim Cho, 3/1/2020-2/28/2024, $454,410 ($91,666/year)

OSC, Mobile-Health Delivery of Lifestyle Interventions for Women with Breast Cancer- NCORP Pilot Trial, #TBA, Wake Forest University Baptist Medical Center, PI - Lorenzo Cohen, 8/1/2020-7/31/2021, $74,994 ($74,994/year)

Collaborator, 1%, Integrating acupuncture into postoperative pain management in patients undergoing open abdominal operations, #TBA, MDACC Institutional Research Grant, PI - Wenli Liu, 8/12/2020-5/31/2022, $375,000 ($75,000/year)

Co-Investigator, 3%, Comparative Modeling of Precision Breast Cancer Control Across the Translational Continuum – Supplement, 3U01CA253911-02S1, NIH/NCI, PI - Amy Trentham-Dietz, 9/1/2021-8/31/2023, $110,160

Co-Investigator, 1%, Mobile-Health Delivery of Lifestyle Interventions for Women with Breast Cancer - Weil Pilot Trial, FP00015858, Weil Foundation, PI - Lorenzo Cohen, 7/1/2022-6/30/2023, $88,349 ($88,349/year)

Co-Investigator, 1%, Harmony & Health: Feasibility of a movement intervention to improve psychosocial wellbeing in Black adults in Northeast Texas, #TBA, MD Anderson Duncan Family Institute (DFI) Seed Funding Program, PI - Scherezade Kelly Mama, 8/1/2022-7/31/2024, $100,000 ($50,000/year)

**Not Funded**

Co-Investigator, 10%, Neurobiological correlates of depression in cancer, 1 DP2 OD003220 01, NIH/Office of the Director, PI - Eileen Huh Shinn, 9/28/2007-8/31/2012, $1,397,700 ($279,540/year)

Co-Investigator, 10%, An interactive text messaging smoking cessation intervention for HIV+ smokers, 1 DP2 OD001765 01, NIH/Office of the Director, PI - Damon J. Vidrine, 9/30/2007-8/31/2012, $1,500,000 ($300,000/year)

Significant Contributor, Body image, functional status, and psychological distress during active treatment for nonmelanoma skin cancer, CCTS, PI - Michelle Cororve Fingeret, 12/1/2007-12/30/2009, $50,000 ($50,000/year)

Co-Investigator, 5%, Motivational enhancement for smoking cessation and relapse prevention among Mexican Americans, 1 R01 CA131153 01, NIH/NCI, PI - David W. Wetter, 1/1/2008-12/31/2012, $3,803,342 ($492,394/year)

Co-Investigator, 5%, Neighborhood and Individual-Level Determinants of Smoking Cessation Among Hispanics, NIH/NCMHD, PI - David W. Wetter, 1/1/2008-12/31/2012, $1,011,840 ($203,003/year)

Co-Investigator, 3%, Oral Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use, UTMDACC - Other Internal Funding, PI - David W. Wetter, 1/1/2008-12/31/2012, $3,800,000 ($950,000/year)

Significant Contributor, Quantifying Aesthetic and Body Image Outcomes of Breast Cancer Reconstruction, 1 R03 CA135024 01, NIH/NCI, PI - Michelle Cororve Fingeret, 7/1/2008-6/30/2010, $100,000 ($50,000/year)

Co-Investigator, 5%, Physical activity after breast cancer: an RCT implemented in a healthcare setting, 1 R01 CA128921 01A2, NIH/NCI, PI - Cindy L. Carmack-Taylor, 7/1/2008-6/30/2013, $2,438,139 ($487,628/year)

Principal Investigator, 40%, Default Bayesian Methods for Generalized Linear and Additive Mixed Models, 1 R21 CA137529 01, NIH/NCI, 12/1/2008-11/30/2010, $250,000 ($125,000/year)

Investigator, 1%, Pilot Test of an Intervention to Prevent Cardiovascular Toxicity in Cancer Patients Receiving Targeted Therapies, N/A, American Heart Association, PI - Karen M. Basen-Engquist, 7/1/2009-6/30/2011, $127,272 ($63,636/year)

Investigator, 10%, Determinants of ST Cessation Among American Indians, 1 R01 CA141614 01, NIH/NCI, PI - David W. Wetter, 7/1/2009-6/30/2014, $3,049,865 ($590,711/year)

Co-Investigator, 5%, Preventing cardiovascular toxicity in cancer patients on anti-VEGF therapy, 1 RC1 CA146331 01, NIH/NCI, PI - Karen M. Basen-Engquist, 9/30/2009-9/29/2011, $647,073 ($329,370/year)

Co-Mentor, Between Socioeconomic Status and Behavioral Cancer Risk Factors, 1 K07 CA143051 01, NIH/NCI, PI - Darla Elizabeth Kendzor, 12/1/2009-11/30/2014, $738,739 ($149,904/year)

Co-Mentor, Socioeconomic Disparities in Smoking Cessation: Understanding the Mechanisms, 1 K01 DA029041 01, NIH/NIDA, PI - Michael S. Businelle, 4/1/2010-3/31/2011, $799,606 ($154,151/year)

Co-Investigator, 10%, Neighborhood Quality and Cancer Related-Risk Behaviors Among Mexican Americans, GRANT10341493, NIH/NCI, PI - Lorraine R. Reitzel, 4/1/2010-3/31/2015, $2,628,051 ($442,151/year)

Core Leader, 30%, Biological, Environmental, & Social Determinants of Early-Onset Breast Cancer (PC-A), 1 P50 CA148083 01, NIH/NCI, PI - Lovell A. Jones, 4/10/2010-3/30/2015, $753,037 ($141,956/year)

Collaborator, 5%, Enhancing Tobacco and Alcohol Treatment among OEF/OIF Veterans, 1 R01 DA030158 01, NIH/NIDA, PI - Jennifer Irvin Vidrine, 7/1/2010-6/30/2015, $2,821,536 ($558,546/year)

Co-Mentor, Developing a Culturally Relevant Model of Smoking Cessation, 1 K01 HL103153 01, NIH/NHLBI, PI - Yessenia Castro, 9/1/2010-8/31/2015, $557,455 ($111,491/year)

Core Director, 3%, Biological, Environmental, & Social Determinants of Early-Onset Breast Cancer (PC-B), 1 P01 CA154338 01, NIH/NCI, PI - Lovell A. Jones, 12/1/2010-11/30/2015, $863,024 ($162,671/year)

Biostatistician, 10%, The Effects of Neighborhood Perceptions on Cancer-Related Risk Behaviors/Conditions, 1 R01 CA155002 01, NIH/NCI, PI - Lorraine Reitzel, 12/1/2010-11/30/2015, $2,531,768 ($511,235/year)

Co-Investigator, 5%, Channel Free: empowering parents to promote healthy household media environments, NIH/NCI (Subcontract from Radiant Creative Group), PI - Alex Prokhorov, 7/1/2011-6/30/2012, $135,333 ($135,333/year)

Co-Investigator, 5%, Enhancing Tobacco and Alcohol Treatment Among Veterans, 1 R01 CA160832 01, NIH/NCI, PI - Jennifer Irvin Vidrine, 7/1/2011-6/30/2016, $2,674,684 ($507,452/year)

Co-Director, 5%, Project EXPORT (Excellence in Partnership, Outreach, Research, and Training), RFA-MD-11-003, NIH/NCMHD (Subcontract from University of Houston), PI - Robin Fuchs-Young, 1/1/2012-12/31/2016, $5,750,000 ($950,000/year)

Co-Investigator, 10%, An evidence-based smoking cessation program for underserved persons living with HIV/AIDS, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Damon Vidrine, 3/1/2012-2/28/2015, $993,368 ($331,123/year)

Co-Investigator, 10%, Smoking Cessation Treatment for Underserved Survivors of Cervical Cancer, Cancer Prevention Research Institute of Texas (CPRIT), Cancer Prevention & Research Institute of Texas (CPRIT), PI - Jennifer Irvin Vidrine, 3/1/2012-2/28/2015, $1,452,108 ($484,036/year)

Co-Director, 15%, Biological, Environmental and Social Determinants of Early-Onset Breast Cancer, 1 P01 CA154338 01A1, NIH/NCI, PI - Lovell Jones, 4/1/2012-3/31/2017, $1,168,420 ($220,078/year)

Co-Investigator, 5%, Childhood trauma and smoking: Role of interpersonal stress and emotion regulation, 1 R01CA166659-01, NIH/NCI, PI - Janice Blalock, 4/1/2012-3/31/2017, $1,916,290 ($589,012/year)

Co-Investigator, 5%, Smoking Cessation for Underserved Cervical Cancer Survivors, 1 R01MD007037-01, NIH/NCI, PI - Jennifer Irvin Vidrine, 4/1/2012-3/31/2017, $1,361,248 ($268,474/year)

Co-Investigator, 1%, Behaviors related to cancer risk among African-American college students, NIH (Subcontract from Prairie view A&M University), PI - Kentya Ford, Alexandre V Prokhorov, 7/1/2012-6/30/2014, $12,377 ($6,127/year)

Co-Investigator, 15%, Integration of evidence-based tobacco treatments into primary care clinics, 1 R01DA034246 01, NIH/NIDA, PI - Ludmila Cofta-Woerpel, 7/1/2012-6/30/2015, $1,505,438 ($498,699/year)

Co-Investigator, 5%, Making a Case for Quitting: An Interactive Approach to Cessation in HIV+ Smokers, 1 R01 CA163098-01A1, NIH/NCI, PI - Damon J. Vidrine, 7/1/2012-6/30/2017, $2,335,559 ($459,006/year)

Co-Investigator, 10%, Contextual determinants of multiple risk factors among an African American cohort, 1 R01 CA172324 01, NIH/NCI, PI - Lorna McNeill, 9/1/2012-8/31/2017, $2,484,943 ($499,958/year)

Co-Investigator, 5%, A Faith-Based Partnership to Address Cancer Disparities in African Americans, 1 R24 MD008059-01, NIH/NIMH, PI - Lorna McNeill, 1/1/2013-12/31/2015, $750,000 ($250,000/year)

Co-Investigator, 2%, Move On Up - a web-based lifestyle intervention for hematologic survivors, American Cancer Society (ACS), PI - Raheem Paxton, 1/1/2013-12/31/2016, $767,183 ($191,796/year)

Co-Investigator, 10%, Environmental Determinants of Cancer Risk Behaviors Among African Americans, American Cancer Society (ACS), PI - Lorraine Reitzel, 1/1/2013-12/31/2017, $1,998,485 ($399,915/year)

Co-Investigator, 10%, Peer Support for Colorectal Cancer Screening Among African Americans, American Cancer Society (ACS), PI - Lorna McNeill, 1/1/2013-12/31/2017, $1,998,485 ($399,697/year)

Co-Investigator, 5%, Smoking Cessation Treatment for Underserved Survivors of Cervical Cancer, American Cancer Society (ACS), PI - Jennifer Irvin Vidrine, 1/1/2013-12/31/2017, $1,999,483 ($399,897/year)

Co-Investigator, STTN, PI - Karen Basen-Engquist, 2013

Co-Investigator, 10%, Comprehensive Integration of Genomic Information in Managing Women's Cancers, 1UM1HG007330-01, NIH/National Human Genome Research Institute, PI - John Mendelsohn, 3/1/2013-2/28/2017, $5,993,249 ($1,498,320/year)

Co-Investigator, 10%, Implementing Genomically-Informed Personalized Therapy as Standard of Care, 1 U01 HG007286-01, NIH/National Human Genome Research Institute, PI - Funda Meric-Bernstam, 4/1/2013-3/31/2017, $2,747,605 ($560,633/year)

Co-Investigator, Bayesian methods for cancer, behavioral, and muscular dystrophy studies, R01, NIH (Subcontract from University of Texas - Austin), PI - Michael Daniels, 7/1/2013-6/30/2018, $64,205 ($12,841/year)

Co-Investigator, 10%, NEXT Steps: RCT of Tailored Weight Loss Intervention for Endometrial Ca Survivors, 1 R01 CA169073-01A1, NIH/NCI, PI - Karen Basen-Engquist, 7/1/2013-6/30/2018, $2,919,229 ($598,702/year)

Core-Director, 10%, NIMHD Transdisciplinary Collaborative Center for Men's Health Research (CMHR), 1 U54 MD008618-01, NIH/NIMHD, PI - Lovell Jones, 7/1/2013-6/30/2018, $545,681 ($56,937/year)

Co-Investigator, 1%, Steps to Health: Real-time Intervention for Exercise in Cancer Survivors, Santech, Inc., PI - Karen Basen-Engquist, 12/1/2013-5/31/2016, $427,143 ($170,857/year)

Co-Investigator, 15%, Integration of evidence-based tobacco treatments into primary care clinics, 1R01DA035779-01A1, NIH, PI - Ludmila Cofta-Woerpel, 4/1/2014-3/31/2017, $1,492,400 ($494,262/year)

Co-Investigator, 10%, Physician-Pharmacist Model for Increasing Physical Activity in Safety Net Clinics, 1 R01HD079643-01, NIH, PI - Lorna Haughton McNeill, 4/1/2014-3/31/2019, $2,648,869 ($537,239/year)

Co-Investigator, 10%, Stress, Socioeconomic Status, Obesity, and Fatigue in Breast Cancer Survivors, 1 R01CA184054-01, NIH/NCI, PI - Christopher Fagundes, 4/1/2014-3/31/2019, $2,499,982 ($499,996/year)

Co-Investigator, 1%, Development of a Couple-Based Mind-Body Program for Glioma Patients and Partners, 1R03CA188001-01, NIH/NCI, PI - Kathrin Milbury, 7/1/2014-6/30/2016, $100,000 ($50,000/year)

Co-Investigator, 10%, Cancer-related fatigue, autonomic activity, and inflammation: a prospective study, 1R01CA188109-01, NIH/NCI, PI - Christopher Fagundes, 7/1/2014-6/30/2019, $2,168,215 ($430,176/year)

Co-Investigator, 10%, Fatigue, autonomic activity, socioeconomic position, and inflammation, American Cancer Society (ACS), PI - Christopher Fagundes, 7/1/2014-6/30/2019, $1,913,228 ($382,646/year)

Co-Mentor, Health Literacy and Smoking Cessation in Low-SES, Diverse Smokers, 1K07CA188152-01, NIH/NCI, PI - Diana Williams Stewart, 7/1/2014-6/30/2019, $563,715 ($112,920/year)

Co-Investigator, 10%, Using Mobile Technology to Treat Underserved Smokers in Inner City Neighborhoods, 1R01CA187137-01, NIH/NCI, PI - Damon Vidrine, 7/1/2014-6/30/2019, $2,648,476 ($508,908/year)

Co-Investigator, 5%, Managing weight during neoadjuvant chemotherapy for breast ca: biomarker effects, 1R01CA190367-01, NIH/NCI, PI - Karen Basen-Engquist, 9/1/2014-8/31/2019, $2,493,856 ($497,996/year)

Collaborator, 20%, NCI Community Oncology Research Program (NCORP) Research Bases, NIH/NCI, PI - Michael J. Fisch, 9/1/2014-8/31/2019, $23,944,007 ($2,983,208/year)

Co-Investigator, 5%, A pilot study of massage to treat chemotherapy induced peripheral neuropathy, 1 R03CA182563-01A1, NIH/NCI, PI - Gabriel Lopez, 12/1/2014-11/30/2016, $100,000 ($50,000/year)

Co-Investigator, 1%, Self-administered meditation intervention for cancer patients with moderate to severe self-reported anxiety, Mike Hogg Fund, PI - Gabriel Lopez, 1/1/2015-12/31/2015, $23,080

Co-Investigator, 1%, Couple-based meditation program for lung cancer patients and partners, American Cancer Society (ACS), PI - Kathrin Milbury, 1/1/2015-12/31/2016, $119,006 ($119,006/year)

Co-Investigator, 2%, Effect of Exercise on Visceral Adipose and a Novel Ovarian Cancer-Related Biomarker: Dose effects and feasibility in ovarian cancer survivors, American Institute for Cancer Research (AICR), PI - Karen Basen-Engquist, 1/1/2015-12/31/2017, $224,785 ($224,785/year)

Co-Investigator, 5%, Omental adipose tissue in ovarian cancer progression, Ovarian Cancer Research Fund, PI - Samuel Mok, 1/1/2015-12/31/2017, $900,000 ($81,818/year)

Collaborator, 10%, How Much is Enough? Effect of Exercise Dose on Biomarkers Related to Cancer Risk and Recurrence in Post-Menopausal Women, RP 150187, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Karen Basen-Engquist, 3/1/2015-2/28/2018, $1,605,016 ($535,005/year)

Co-Investigator, 10%, Integration of evidence-based tobacco treatments into primary care clinics, RP150019, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Ludmila Cofta-Woerpel, 3/1/2015-2/28/2018, $1,418,174 ($472,725/year)

Co-Investigator, 10%, Physician-Pharmacist Model for Increasing Physical Activity in Safety Net Clinics, 39139, Cancer Prevention & Research Institute of Texas (CPRIT), PI - McNeill, 3/1/2015-2/28/2018 ($1,765,096/year)

Co-Investigator, 5%, Development of a Couple-Based Mind-Body Program for Glioma Patients and Partners, 1 R21 CA194898-01, NIH/NCI, PI - Kathrin Milbury, 4/1/2015-3/31/2017, $275,000 ($150,000/year)

Co-Investigator, 5%, Placebo controlled trial of acupuncture for chronic post-mastectomy pain, 1 R21 CA194951-01, NIH/NCI, PI - Kay Garcia, 4/1/2015-3/31/2017, $275,000 ($125,000/year)

Co-Investigator, 5%, Guided Meditation during Stereotactic Breast Biopsy, 1R01CA187153-01A1, NIH/NCI, PI - Lorenzo Cohen, 4/1/2015-3/31/2019, $1,000,000 ($250,000/year)

Co-Investigator, 10%, Cancer-related fatigue, autonomic activity, and inflammation: a prospective study, 1 R01CA188109-01, NIH/NCI, PI - Christopher Fagundes, 4/1/2015-3/31/2020, $3,770,088 ($430,176/year)

Co-Investigator, 15%, Fatigue, Herpevirus Latency and Inflammation in Breast Cancer Survivors, NIH/NCI, PI - Christopher Fagundes, 4/1/2015-3/31/2020, $2,252,557 ($442,869/year)

Co-Investigator, 2%, Diet, stress and inflammation: Pathways to cancer disparities, 332274, Susan G. Komen Breast Cancer Foundation, PI - Christopher Fagundes, 5/1/2015-4/30/2018, $312,809 ($101,751/year)

Co-Principal Investigator, 25%, Prevention of obesity-related cancer initiation and progression by weight loss and physical activity: Exploring the mechanisms and therapeutic opportunities, RFA R-15-MIRA02, Cancer Prevention and Research Institute of Texas (CPRIT) MIRA, PI - Karen Basen-Engquist, 6/1/2015-5/31/2020, $8,741,020 ($1,739,464/year)

Co-Investigator, 10%, Pathways Linking Acculturation and Obesity Risk in Mexican Americans, 1R01 MD 009716-01, NIH, PI - Larkin Strong, 6/30/2015-6/29/2019, $223,436,781 ($362,896/year)

Co-Investigator, 10%, Pathways Linking Acculturation and Obesity Risk in Mexican Americans, 1 R01 MD008986-01, NIH, PI - Larkin Strong, 6/30/2015-6/29/2019 ($362,896/year)

Co-Investigator, 5%, Development of a couple-based yoga program for glioma patients and partners, PAR-13-146, NIH/NCI, PI - Kathrin Milbury, 7/1/2015-6/30/2017, $456,412 ($275,000/year)

Co-Investigator, 5%, Examining the Neural Substrates of Acupuncture for Radiation-Induced Xerostomia, R01 CA197643-01, NIH/NCI, PI - Lorenzo Cohen, 7/1/2015-6/30/2019, $513,158 ($2,047,085/year)

Co-Investigator, 5%, Hostility, Marital Interaction, and Cancer Survivorship, 1 R01 CA196998-01, NIH, PI - Christopher Fagundes, 7/1/2015-6/30/2020, $3,610,724 ($464,568/year)

Co-Investigator, 5%, Hostility, Marital Interaction, and Cancer Survivorship, 345271, American Cancer Society (ACS), PI - Christopher Fagundes, 7/1/2015-6/30/2020, $2,287,749 ($395,077/year)

Co-Investigator, 10%, Pathways to Cancer Disparities: A Biobehavioral Approach to Symptom Burden, 1 R01CA196987-01, NIH, PI - Christopher Fagundes, 7/1/2015-6/30/2020, $3,917,662 ($492,746/year)

Co-Investigator, 5%, Pathways to Cancer Disparities: A Biobehavioral Approach to Symptom Burden, 345262, American Cancer Society (ACS), PI - Christopher Fagundes, 7/1/2015-6/30/2020, $2,325,065 ($382,078/year)

Co-Investigator, 10%, Physician-Pharmacist Model for Increasing Physical Activity in Safety Net Clinics, 338036, American Cancer Society (ACS), PI - Loren McNeill, 7/1/2015-6/30/2020, $2,369,324 ($408,871/year)

Co-Investigator, 1%, Physician-Pharmacist Model for Increasing Physical Activity in Safety Net Clinics, 1 R01 CA196864-01, NIH/NCI, PI - Lorna McNeill, 7/1/2015-6/30/2020, $3,841,188 ($501,779/year)

Co-Investigator, 10%, Biobehavioral Outcomes and Mechanisms of a Comprehensive Lifestyle Intervention for Women with Breast Cancer, 1 R01 CA201239-01, NIH/NCI, PI - Lorenzo Cohen, 9/1/2015-8/31/2020, $3,284,945 ($656,989/year)

Co-Investigator, 5%, Using game mechanics to improve outcomes among stem cell transplant, Radiant Creative group, 12/1/2015-11/30/2018 ($190,724/year)

Co-Investigator, 2%, Effect of two exercise types on visceral adipose and a novel ovarian cancer-related biomarker: modality effects and feasibility in cancer survivors, 15091612, American Institute for Cancer Research (AICR), PI - Karen Basen-Engquist, 1/1/2016-12/31/2018, $224,714 ($112,357/year)

Collaborator, 5%, Targeting Glycolysis and Energy Efficiency for Effective and Safe Prevention of ER-negative Breast Cancer, DOD BC150175, Department of Defense (DOD), PI - Qiang Shen, 1/1/2016-12/31/2018 ($147,581/year)

Collaborator, 3%, Targeting Glycolysis Pathway for Estrogen Receptor-negative Breast Cancer Chemoprevention, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Qiang Shen, 3/1/2016-2/28/2019, $502,347 ($170,454/year)

Co-Investigator, 5%, Couple-Based Yoga Program for Glioma Patients and Their Partners, 1R21CA194898-01A1, NIH, PI - Kathrin Milbury, 4/1/2016-3/31/2018, $285,006 ($155,003/year)

Co-Investigator, 5%, A novel peer and family-based approach to obesity in African American families, 1U01MD010641-01, NIH, PI - Lorna McNeil, 4/1/2016-3/31/2021, $1,748,983 ($349,910/year)

Co-Investigator, 10%, Meditation for the Treatment of Cognitive Dysfunction after Chemotherapy for Women with Breast Cancer: A Randomized Controlled Trial, 1R01CA204964-01, NIH, PI - Lorenzo Cohen, 4/1/2016-3/31/2021, $2,473,698 ($497,992/year)

Co-Investigator, 5%, Neuroplasticity-based Behavioral Interventions for Cancer-Related Cognitive Impairment, 1 R01 NR01622-01, NINR, PI - Shelli Kesler, 4/1/2016-3/31/2021 ($318,132/year)

Co-Investigator, 5%, Neurofeedback to treat Aromatase-Induced Arthralgia in Breast Cancer Survivors, FP00000062, NIH/NCI, PI - Sarah Prinsloo, 7/1/2016-6/30/2018, $275,000 ($150,000/year)

Co-Investigator, 5%, Examining the Neural Substrates of Acupuncture for Radiation-Induced Xerostomia, 1R01CA197643-01A1, NIH/NCI, PI - Lorenzo Cohen, 7/1/2016-6/30/2020, $2,017,675 ($486,951/year)

Co-Investigator, 5%, Biobehavioral effects of Yoga versus CBT for women with breast cancer experiencing depressive symptoms and undergoing radiotherapy, 1R01CA207186-01, NIH/NCI, PI - Lorenzo Cohen, 7/1/2016-6/30/2021, $2,479,779 ($499,411/year)

Co-Investigator, 10%, Biobehavioral Outcomes and Mechanisms of a Comprehensive Lifestyle Intervention for Women with Breast Cancer., 1R01CA201239-01A1, NIH/NCI, PI - Lorenzo Cohen, 7/1/2016-6/30/2021, $3,414,844 ($698,360/year)

Principal Investigator, 30%, Mechanism-based early phase adaptive clinical trial designs in oncology using pharmacokinetics-pharmacodynamics modeling, 1R01CA212015-01, NIH/NCI, 9/1/2016-8/31/2020, $1,207,815 ($301,805/year)

Co-Investigator, 5%, Watchful Living: A lifestyle intervention for African American Prostate Cancer Patients on Active Surveillance and their spouses, DFI, Duncan Family Institute For Cancer Prevention and Risk Assessment, PI - Cassandra Diep, 12/1/2016-11/30/2018, $98,432 ($49,216/year)

Principal Investigator, 35%, Mechanism-based early phase adaptive clinical trial designs in oncology using pharmacokinetic-pharmacodynamic modeling, RFA R-17.1-IIRA, Cancer Prevention & Research Institute of Texas (CPRIT), 12/1/2016-11/30/2019, $900,000 ($300,000/year)

Co-Investigator, 5%, Watchful Living: A lifestyle intervention for African American Prostate Cancer Patients on Active Surveillance and their spouses, IRG, Institutional Research Grant, PI - Cassandra Diep, 2/1/2017-1/31/2019, $76,671 ($38,336/year)

Co-Investigator, Reduced Sugar Feeding Study in Women with Early-Stage Breast Cancer, FP00001024, Laura and John Arnold Foundation, PI - Cohen, Lorenzo / Yang, Peiying, 7/1/2017-6/30/2018, $502,340 ($502,340/year)

Co-Investigator, Neurofeedback to Treat Aromatase-Induced Arthralgia In Breast Cancer Survivors, 1R21CA220185-01, NIH, PI - Prinsloo, Sarah, 7/1/2017-6/30/2019, $150,000 ($75,000/year)

Co-Investigator, 7%, Yoga Program for Couples Coping with Lung Cancer, FP00000074, American Cancer Society (ACS), PI - Kathryn Milbury, 7/1/2017-6/30/2021, $549,997 ($250,000/year)

Principal Investigator, 30%, Mechanism-based early phase adaptive clinical trial designs in oncology using pharmacokinetic-pharmacodynamic modeling, FP00000705, NIH/NCI, 7/1/2017-7/1/2021, $1,208,615 ($301,158/year)

Co-Investigator, 5%, A peer and family-based approach to obesity in African American families, FP00000443, American Cancer Society (ACS), PI - Lorna McNeill, 7/1/2017-6/30/2022, $1,965,198 ($382,868/year)

Co-Investigator, Biobehavioral Effects of Yoga versus CBSM for Women with Breast Cancer Experiencing Depressive Symptoms and Undergoing Radiotherapy, FP00000489, NIH/NCI, PI - Cohen, Lorenzo, 7/1/2017-6/30/2022, $1,486,282 ($743,141/year)

Collaborator, 5%, Targeting Glucose and Energy Metabolism for Breast Cancer Chemoprevention, 1R01CA211699-01A1, NIH/NCI, PI - Qiang Shen, 7/1/2017-6/30/2022, $2,679,674 ($481,786/year)

Co-Investigator, 10%, Yoga Program for Couples Coping with Lung Cancer, 1R01CA218097-01, NIH/NCI, PI - Kathrin Milbury, 7/1/2017-6/30/2022, $1,250,000 ($250,000/year)

Co-Investigator, 5%, A Dyadic Psychosocial Intervention for Black Prostate Cancer Survivors Undergoing Active Surveillance, 1R21NR017447-01, NIH, PI - Cassandra Diep Yeung, 9/1/2017-8/31/2019, $275,000 ($150,000/year)

Co-Investigator, 5%, Online Dyadic Mind-Body Intervention for Brain Tumor Patients and their Caregivers, 1R21CA223644-01, NIH/NCI, PI - Kathrin Milbury, 12/1/2017-11/30/2019, $275,000 ($137,500/year)

Co-Investigator, 5%, BC170211: Developing HJC0152 as a Targeted Therapy for Metastatic Breast Cancer, FP00002862, DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP), PI - Qiang Shen, 3/1/2018-2/28/2021, $609,041 ($200,082/year)

Co-Investigator, 5%, A family-based approach to reducing obesity risk among African American families, 1R21NR017425-01A1, NIH, PI - Lorna McNeill, 4/1/2018-3/31/2020, $275,000 ($137,500/year)

Co-Investigator, 10%, A multi-level analysis to identify factors associated with unhealthy sleep duration and disparity among Mexican Americans, 1R01MD012733-01, NIH/NCI, PI - Hua Zhao, 4/1/2018-3/31/2022, $1,943,036 ($498,483/year)

Co-Investigator, 10%, Yoga Program for Couples Coping with Lung Cancer, 1R01CA218097-01A1, NIH/NCI, PI - Kathrin Milbury, 4/1/2018-3/31/2023, $1,250,000 ($250,000/year)

Co-Investigator, 7%, Yoga Program for Couples Coping with Lung Cancer, 560095, American Cancer Society (ACS), PI - Kathrin Milbury, 7/1/2018-6/30/2022, $639,991 ($159,998/year)

Co-Investigator, 5%, Comprehensive Lifestyle Intervention versus Conventional Health Coaching for Overweight Women with Breast Cancer: Mechanisms and Biobehavioral Outcomes, 1R01CA231444-01, NIH/NCI, PI - Lorenzo Cohen, 7/1/2018-6/30/2023, $2,499,784 ($499,957/year)

Co-Investigator, 1%, Measuring, Modeling, and Preventing Chemotherapy-induced Peripheral Neuropathy: The Role of Neurological Mechanisms and Neurofeedback, 1R01CA231010-01 / FP00003470, NIH/NCI, PI - Sarah Prinsloo, 7/1/2018-6/30/2023, $1,316,328 ($263,266/year)

PD/PI, 30%, Mechanism-based early phase adaptive clinical trial design in oncology, 1R01CA231564-01 / FP00003670, NIH/NCI, PI - Yisheng Li, 7/1/2018-6/30/2023, $1,509,091 ($301,818/year)

Co-Principal Investigator, 15%, Modeling the risk of significant liver fibrosis in obesity and diabetes, FP00004368, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Laura Beretta, 8/31/2018-8/30/2022, $5,808,954 ($1,452,238/year)

Co-Investigator, 5%, Role of HIPK4 in Cancer Metastasis and the Development of HIPK4-targeting Therapy, 1R01CA233623-01 /FP4734, NIH/NCI, PI - Qiang Shen, 9/1/2018-8/31/2023, $1,413,875 ($282,775/year)

Co-Investigator, 5%, Examination of the effects of dietary sugar in tumorigenesis and metastasis of breast cancer, FP00003237 / BC170074, Department of Defense (DOD), PI - Peiying Yang / Lorenzo Cohen, 10/1/2018-9/30/2022, $1,846,569 ($449,822/year)

Co-Investigator, 1%, Feasibility of Delivering a Mobile-Health Comprehensive Lifestyle Intervention for Overweight Women with Breast Cancer, 1R21CA234886-01 / FP4585, NIH/NCI, PI - Lorenzo Cohen, 12/1/2018-11/30/2020, $275,000 ($150,000/year)

Biostatistician, 5%, Reducing breast cancer risk through modifying body composition and decreasing inflammation in normal weight women, FP00005679, American Institute for Cancer Research (AICR), PI - Karen Basen-Engquist, 1/1/2019-12/31/2021, $228,669 ($76,221/year)

Co-Investigator, 1%, Optimizing Treatments for Chemotherapy-Induced Peripheral Neuropathy, FP00005185, American Cancer Society (ACS), PI - Sarah Prinsloo, 1/1/2019-12/31/2022, $632,783 ($164,034/year)

Co-Investigator, 10%, Weight Control Intervention in Obese and/or Diabetic Adults with Liver Fibrosis, 1R01CA235728-01 / FP00005041, NIH/NCI, PI - Karen Basen-Engquist, 1/1/2019-12/21/2023, $2,406,154 ($499,998/year)

Co-Investigator, 3%, Optimizing Treatments for Chemotherapy-Induced Peripheral Neuropathy: Neurological Mechanisms and Biopsychosocial Processes, 1R01CA235700-01 / FP00004937, NIH/NCI, PI - Sarah Prinsloo, 1/1/2019-12/31/2024, $1,250,000 ($250,000/year)

Collaborator, 5%, The Antitumor Effect of Mistletoe in Hepatocellular Carcinoma via Downregulation of myc Signaling and Metabolism, FP00004864, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Peiying Yang, 3/1/2019-2/28/2022, $85,282,620 ($28,461,140/year)

Biostatistician, 5%, Reducing breast cancer risk through modifying body composition and decreasing inflammation in normal weight women, 1R21CA239079-01, NIH/NCI, PI - Karen Basen-Engquist, 4/1/2019-3/31/2021, $291,998 ($133,499/year)

Co-Investigator, 10%, Acculturation trajectories and sleep problems among Mexican Americans, 1R01MD014016-01, NIH/NCI, PI - Hua Zhao, 4/1/2019-3/31/2023, $1,506,263 ($384,455/year)

Statistician, A Pilot Study of Function-Preserving Radiosurgery for Brain Metastases, FP00007655, Radiation Oncology Institute, PI - Samantha Buszek, 5/1/2019-4/30/2021, $46,717 ($23,358/year)

Other Significant Contributor, Multi-Modal Psychoeducation for Patients with Advanced Cancer Parenting Minor Children, FP00007332, National Palliative Care Research Center, PI - Kathrin Milbury, 7/1/2019-6/30/2021, $139,989 ($69,994/year)

Co-Investigator, 5%, Biobehavioral Effects of Hypnosis During Breast Cancer Surgery, 1R01CA214527-01A1, National Cancer Institute, PI - Lorenzo Cohen, 7/1/2019-6/30/2023, $1,375,560 ($339,859/year)

Co-Investigator, 1%, Measuring, Modeling, and Preventing Chemotherapy-induced Peripheral Neuropathy: The Role of Neurological Mechanisms and Neurofeedback, 1R01CA231010-01A1, NIH/NCI, PI - Sarah Prinsloo, 7/1/2019-6/30/2024, $1,099,666 ($256,781/year)

Co-Investigator, 1%, Optimizing Neurofeedback as a Treatment for Chemotherapy Induced Peripheral Neuropathy, 1R01NR018650-01, NIH/NCI, PI - Sarah Prinsloo, 7/1/2019-6/30/2024, $188,817 ($392,648/year)

Co-Investigator, 1%, Peer-based approaches to enhance physical activity in inactive women, FP00006709, American Cancer Society (ACS), PI - Larkin Strong, 7/1/2019-6/30/2024, $1,959,552 ($386,577/year)

Co-Investigator, 10%, Peer-based Approaches to Enhance Social Support for Physical Activity in Dyads of Inactive Women, 1R01HL148073-01, NIH/NCI, PI - Larkin Strong, 7/1/2019-6/30/2024, $2,529,968 ($475,893/year)

Co-Investigator, 10%, The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma - Core 2: Biostatistics and Bioinformatics, 1P50CA217674-01A1, NIH/NCI, PI - Laura Beretta, 7/1/2019-6/30/2024, $834,625 ($166,925/year)

Co-Investigator, 10%, Parenting Intervention for Families Coping with Advanced Cancer, 1R21NR018929-01, NIH/NCI, PI - Kathrin Milbury, 9/1/2019-8/31/2021, $275,000 ($150,000/year)

Co-Investigator, 1%, Optimizing Neurofeedback to Treat Chemotherapy Induced Peripheral Neuropathy, FP00007576, Rising Tide Foundation, PI - Sarah Prinsloo, 9/1/2019-8/31/2022, $407,104 ($134,330/year)

Co-Investigator, 5%, Mechanisms and Biobehavioral Outcomes of Lifestyle Interventions for Overweight Women with Breast Cancer, 1R01CA244173-01, NIH/NCI, PI - Lorenzo Cohen, 9/1/2019-8/31/2024, $242,683 ($472,717/year)

Co-Investigator, 10%, Multicenter trial to investigate neurofeedback as a treatment for chemotherapy-induced peripheral neuropathy, FP00006484, Rising Tide Foundation, PI - Sarah Prinsloo, 9/1/2019-8/31/2024, $1,610,245 ($339,513/year)

Co-Investigator, 1%, Multicenter trial to investigate neurofeedback as a treatment for chemotherapy-induced peripheral neuropathy, 1R21CA220185-01A1, NIH/NCI, PI - Sarah Prinsloo, 9/1/2019-8/31/2024, $200,582 ($415,898/year)

Mentor, Sleep, Stress, and Physical Activity: A Sleep Extension Intervention for Obese/Overweight, Sedentary, and Sleep Deprived African Americans, 1K99HL150834-01, NIH/NCI, PI - Ivan Wu, 9/12/2019-9/11/2024, $658,480 ($95,848/year)

Co-Investigator, 3%, Neurofeedback to Treat Aromatase-Induced Arthralgia In Breast Cancer Survivors, 1R21CA220185-01A1, NIH/NCI, PI - Sarah Prinsloo, 11/1/2019-10/31/2021, $275,000 ($150,000/year)

Co-Investigator, 10%, Writing to Heal: A Culturally Based Brief Expressive Writing Intervention for Chinese Immigrant Breast Cancer Survivors, 1R01CA240790-01, NIH/NCI, PI - Qian Lu, 11/1/2019-10/31/2024, $2,499,263 ($489,822/year)

Co-Investigator, 3%, Therapeutic Potential and Immune Mechanisms Involved with Euphorbia Tirucalli in Cancer, 1R01CA246481-01, NIH/NCI, PI - Peiying Yang, 12/1/2019-11/30/2023, $399,876 ($99,969/year)

Co-Investigator, 10%, Improving Health Utilization and Quality of Life in Head and Neck Cancer Patients Undergoing Chemoradiation and their Family Caregivers, 1R01CA247307-01, NIH/NCI, PI - Kathrin Milbury, 12/1/2019-11/30/2024, $1,682,902 ($321,612/year)

Co-Investigator, 1%, Multi-Modal Parenting Intervention for Families Coping with Advanced Cancer, #TBA, American Cancer Society (ACS), PI - Kathrin Milbury, 1/1/2020-12/31/2021, $119,994 ($59,997/year)

Co-Investigator, 1%, Mobile-Health Delivery of a Comprehensive Lifestyle Intervention for Overweight Women with Breast Cancer: Mechanisms and Biobehavioral Outcomes, #TBA, Gateway for Cancer Research, PI - Gabriel Lopez, 1/1/2020-12/31/2022, $739,754 ($250,251/year)

Co-Investigator, Reducing breast cancer risk through modifying body composition and decreasing inflammation in normal weight women, FP00005679\_Res1, American Institute for Cancer Research (AICR), PI - Karen Basen-Engquist, 1/1/2020-12/31/2022, $224,986 ($74,998/year)

Co-Investigator, 2%, Neurofeedback to Treat Aromatase-Induced Arthralgia, #TBA, American Cancer Society (ACS), PI - Sarah Prinsloo, 1/1/2020-12/31/2023, $477,641 ($131,759/year)

Co-Investigator, 5%, Writing to Heal: The Health Benefits among Chinese Breast Cancer Survivors, #TBA, American Cancer Society (ACS), PI - Qian Lu, 1/1/2020-12/31/2024, $1,986,188 ($388,766/year)

Evaluator, 6%, Promoting HPV Vaccination among College Students in rural and medically underserved areas in Texas, PP20022, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Qian Lu, 3/1/2020-2/28/2023, $949,542 ($313,516/year)

co-PD/PI, 10%, MD Anderson Sarcoma SPORE, 1P50CA247709-01, NIH/NCI, PI - Andrew Futreal, 4/1/2020-3/31/2025, $6,439,485 ($1,288,822/year)

Co-Investigator, 5%, Mobile-Health Delivery of Lifestyle Interventions for Overweight Women with Breast Cancer: Mechanisms and Biobehavioral Outcomes, 1R01CA248426-01, NIH/NCI, PI - Lorenzo Cohen, 4/1/2020-3/31/2025, $2,402,143 ($474,159/year)

Co-Investigator, 5%, Opioid-Sparing Effects of Hypnosis during Breast Cancer Surgery, 1R01CA248208-01, NIH/NCI, PI - Lorenzo Cohen, 4/1/2020-3/31/2025, $1,962,729 ($382,360/year)

Co-Investigator, 5%, Peer-based Approaches to Enhance Social Support for Physical Activity in Dyads of Inactive Women, 1R01HL148073-01A1, NIH/NCI, PI - Larkin Strong, 4/1/2020-3/31/2025, $2,541,692 ($508,330/year)

Co-Investigator, 5%, Promoting HPV Vaccination among Young Adults, 1R01CA248216-01, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Qian Lu, 4/1/2020-3/31/2025, $2,390,461 ($465,466/year)

Co-Investigator, 10%, Writing to Heal: A Culturally Based Brief Expressive Writing Intervention for Chinese Immigrant Breast Cancer Survivors, 1R01CA248213-01, NIH/NCI, PI - Qian Lu, 4/1/2020-3/31/2025, $2,488,318 ($495,624/year)

Statistician, 5%, Anatomical and Functional Imaging-Based Mathematical Model to Predict Response to Immunotherapy in Patients with Melanoma Brain Metastases, #TBA, Conquer Cancer Foundation, PI - Karine Al Feghali, 7/1/2020-6/30/2021, $47,500 ($49,999/year)

Co-Investigator, 2%, Influence of Medicinal Mushrooms on Human Xenobiotic Metabolizing Enzymes and Transporters, 1R21AT011089-01, NIH/NCCIH, PI - Peiying Yang, 7/1/2020-6/30/2022, $343,309 ($155,536/year)

Co-Investigator, 4%, A peer-based approach to enhance physical activity in inactive women, #TBA, American Cancer Society (ACS), PI - Larkin Strong, 7/1/2020-6/30/2025, $2,008,127 ($401,122/year)

Co-Investigator, 5%, Adaptation of a mindfulness-based intervention for Latino cancer patients and their caregivers, 1R01CA253299-01, NIH/NCI, PI - Larkin Strong, 7/1/2020-6/30/2025, $1,339,775 ($278,062/year)

Co-Investigator, 10%, Expressive Writing Intervention to Improve Quality of Life and Mitigate Adverse Outcomes among Ethnically Diverse Young Adult Breast Cancer Survivors, 1U01CA254439-01, NIH/NCI, PI - Qian Lu, 7/1/2020-6/30/2025, $2,394,410 ($462,804/year)

Co-Investigator, 5%, Health Benefits of Writing Therapy among Chinese Breast Cancer Survivors, #TBA, American Cancer Society (ACS), PI - Qian Lu, 7/1/2020-6/30/2025, $1,989,026 ($395,480/year)

Co-Principal Investigator, 10%, MD Anderson Sarcoma SPORE, 1P50CA250951-01, NIH/NCI, PI - Andrew Futreal, 7/1/2020-6/30/2025, $6,874,485 ($1,388,822/year)

Co-Mentor, Social determinants of sleep and obesity: Disparities in African Americans, 1K99MD015296-01, NIH/NCI, PI - Ivan Wu, 7/1/2020-6/30/2025, $640,496 ($89,318/year)

Co-Investigator, 5%, Impacts of Religion and Spirituality on End-of-Life Care Decision-Making: A Multi-Method Longitudinal Study for Adolescents and Young Adults with Advanced Cancer and Their Parents., 1R21CA256592-01, NIH/NCI, PI - Dalnim Cho, 9/1/2020-8/31/2022, $288,163 ($131,434/year)

Co-Investigator, 5%, Parenting Intervention for Caregivers who Parent a Young Child while Caring for a Spouse with an Incurable Cancer., 1R21CA256694-01, NIH/NCI, PI - Kathrin Milbury, 9/1/2020-8/31/2022, $275,000 ($125,000/year)

Co-Investigator, 1%, Leukocyte immune cell profiles and risk of triple negative breast cancer among White and Hispanic women, #TBA, Department of Defense (DOD), PI - Hua Zhao, 9/1/2020-8/31/2023, $986,588 ($319,841/year)

Co-Investigator, 1%, Mobile-Health Delivery of Integrative Medicine Lifestyle Interventions for Breast Cancer Patients During Community Isolation for the COVID-19 Pandemic, #TBA, Gateway for Cancer Research, PI - Lorenzo Cohen, 9/1/2020-8/31/2023, $205,189 ($599,566/year)

Co-Investigator, 5%, Opioid-Sparing Effects of Hypnosis During Breast Cancer Surgery, 1R01CA248208-01A1, NIH/NCI, PI - Lorenzo Cohen, 9/1/2020-8/31/2025, $2,108,269 ($408,601/year)

Co-Investigator, 1%, Multi-Modal Parenting Intervention for Families Coping with Advanced Cancer, #TBA, American Cancer Society (ACS), PI - Kathrin Milbury, 1/1/2021-12/31/2022, $59,965 ($143,916/year)

Co-Investigator, 1%, Mobile-Health Delivery of Integrative Medicine Lifestyle Interventions for Breast Cancer Patients During Community Isolation for the COVID-19 Pandemic, #TBA, Gateway for Cancer Research, PI - Lorenzo Cohen, 1/1/2021-12/31/2023, $205,188 ($599,565/year)

Co-Investigator, 5%, A Multilevel Intervention to Improve HPV Vaccination among Young Adults, 1R01CA256819-01, NIH/NCI, PI - Qian Lu, 1/1/2021-12/31/2025, $1,250,000 ($250,000/year)

Co-Investigator, 4%, A peer-based approach to enhance physical activity in inactive women, #TBA, American Cancer Society (ACS), PI - Larkin Strong, 1/1/2021-12/31/2025, $399,237 ($2,391,055/year)

Co-Investigator, 1%, Dietary magnesium replacement for prevention of hypomagnesemia in ovarian cancer patients receiving platinum-based chemotherapy, 1R21CA260162-01, NIH/NCI, PI - Wenli Liu, 4/1/2021-3/31/2023, $243,000 ($445,500/year)

Co-Investigator, 1%, Navigated Repetitive Transcranial Magnetic Stimulation (nrTMS) to Augment the Effects of Motor Rehabilitation in Brain Tumor Patients, 1R21CA260341-01, NIH/NCI, PI - Sarah Prinsloo, 4/1/2021-3/31/2023, $243,000 ($445,500/year)

Co-Investigator, 1%, Cultural Adaptation of a Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers, 1R34AT011367-01, NIH/NCCIH, PI - Larkin Strong, 4/1/2021-3/31/2024, $296,263 ($741,210/year)

Co-Investigator, 1%, Mobile-Health Delivery of a Comprehensive Lifestyle Intervention for Lymphoma Patients, #TBA, Gabrielles Angel FDN For Cancer Research, PI - Santhosshi Narayanan, 4/1/2021-3/31/2024, $224,995 ($74,998/year)

Co-Investigator, 5%, Mobile-Health Delivery of Lifestyle Interventions for Overweight Women at Risk for Breast Cancer. Mechanisms and Biobehavioral Outcomes, 1R01CA258419-01, NIH/NCI, PI - Lorenzo Cohen, 4/1/2021-3/31/2026, $495,882 ($4,010,728/year)

Co-Investigator, 5%, Mobile-Health Delivery of Lifestyle Interventions for Overweight Women with Breast Cancer: Mechanisms and Biobehavioral Outcomes, 1R01CA248426-01A1, NIH/NCI, PI - Lorenzo Cohen, 4/1/2021-3/31/2026, $805,825 ($4,020,772/year)

Co-Investigator, 10%, Psycho-Spiritual Management for Patients with Advanced Cancer and their Spousal Caregivers, 1R01CA258640-01, NIH/NCI, PI - Kathrin Milbury, 4/1/2021-3/31/2026, $373,659 ($2,949,758/year)

Co-Investigator, 10%, Sleep Disparities among Chinese Immigrant Cancer Survivors, 1R01CA260679-01, NIH/NCI, PI - Qian Lu, 4/1/2021-3/31/2026, $2,537,257 ($4,258,333/year)

Co-Investigator, 10%, Liquid biopsy monitoring in Stages II b/c, and III a/b melanoma, #TBA, Melanoma Research Fndtn, PI - Anthony Lucci, 6/1/2021-5/31/2024, $124,979 ($374,938/year)

Other Significant Contributor, Developing a digital cooking intervention to improve diet and reduce body weight in Hispanic/Latina women with overweight/obesity, 1K99MD016436-01, NIH/NCI, PI - Margaret Raber, 7/1/2021-6/30/2025, $850,662 ($103,662/year)

Co-Investigator, 5%, Biobehavioral Mechanisms and Opioid-Sparing Effects of Hypnosis During Breast Cancer Surgery, R01 CA261999-01, NIH/NCI, PI - Lorenzo Cohen, 7/1/2021-6/30/2026, $797,655 ($3,907,993/year)

Co-Investigator, 10%, Expressive Writing to Reduce Psychological Burden among Chinese Immigrant Breast Cancer Survivors, 1R01CA262378-01, NIH/NCI, PI - Qian Lu, 7/1/2021-6/30/2026, $788,848 ($3,916,406/year)

Core Leader, 15%, MD Anderson Epigenetics SPORE, 1P50CA261606-01, NIH/NCI, PI - Kunal Rai, 7/1/2021-6/30/2026, $11,319,594 ($2,275,108/year)

PD/PI, 10%, MD Anderson Sarcoma SPORE, 1P50CA250951-01A1, NIH/NCI, PI - Richard Gorlick, 7/1/2021-6/30/2026, $2,260,025 ($11,288,253/year)

Co-Investigator, 10%, Writing to Heal: Therapeutic Writing to Improve Quality of Life and Reduce Morbidity among Ethnically Diverse Young Adult Breast Cancer Survivors, 1R01CA261868-01, NIH/NCI, PI - Qian Lu, 7/1/2021-6/30/2026, $809,689 ($4,046,953/year)

Co-Investigator, 2%, Dietary magnesium replacement for prevention of hypomagnesemia in ovarian cancer patients receiving platinum-based chemotherapy, 1R21CA260162-01A1, NIH/NCI, PI - Wenli Liu, 9/1/2021-8/31/2023, $445,500 ($243,000/year)

Co-Investigator, 1%, Multi-Disciplinary Approach to Treatment of Trismus (M-DATT), 1R03DE031392-01, NIH/NIDCR, PI - Richard Cardoso, 9/1/2021-8/31/2023, $324,000 ($162,000/year)

Co-Investigator, 1%, Navigated Repetitive Transcranial Magnetic Stimulation (nrTMS) to Augment the Effects of Motor Rehabilitation in Brain Tumor Patients, 1R21CA260341-01A1, NIH/NCI, PI - Sarah Prinsloo, 9/1/2021-8/31/2023, $445,500 ($243,000/year)

Co-Investigator, 15%, Simulation Modeling to Inform Clinical Translation of Emerging Breast Cancer Therapies, 1R01CA266441-01, NIH subaward via Georgetown University, PI - Xuelin Huang, 9/1/2021-8/31/2025, $1,767,992 ($162,000/year)

Co-Investigator, 5%, Biobehavioral Effects and Mechanisms of Tele-Health Delivery of Lifestyle Interventions for Overweight Women with Breast Cancer, 1R01CA266277-01, NIH/NCI, PI - Lorenzo Cohen, 9/1/2021-8/31/2026, $4,040,207 ($807,119/year)

Co-Investigator, 5%, Bromodomain inhibitors in combination with immune checkpoint blockade agents in melanoma, 1R01CA266065-01, NIH/NCI, PI - Kunal Rai, 9/1/2021-8/31/2026, $4,045,572 ($809,114/year)

Co-Investigator, 2%, Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell Therapy (15th percentile), 1R01CA266714-01, NIH/NCI, PI - Cassian Yee, 9/1/2021-8/31/2026, $3,947,139 ($801,827/year)

Co-Investigator, 5%, Mobile-Health Delivery of Lifestyle Interventions for Overweight Women at Risk for Breast Cancer: Mechanisms and Biobehavioral Outcomes, 1R01CA258419-01A1, NIH/NCI, PI - Lorenzo Cohen, 9/1/2021-8/31/2026, $4,044,073 ($808,007/year)

Co-Investigator, 10%, Virtual Joy Luck Academy: A Culturally Based Digital Intervention for Chinese Immigrant Breast Cancer Survivors, 1R01CA267925-01, NIH/NCI, PI - Qian Lu, 9/1/2021-8/31/2026, $3,792,040 ($766,582/year)

Co-Investigator, 5%, RAPID Rx—DSRCT: The Rapid Advancement of Promising Innovative Drugs (RAPID) for DSRCT, #TBA, LEXS LEMONADE STAND FOUNDATION, PI - Joseph Ludwig, 1/1/2022-12/31/2025, $4,306,846 ($1,071,423/year)

Co-Investigator, Simulation Modeling to Inform Clinical Translation of the Emerging Breast Cancer Therapy, #TBA, American Cancer Society subaward via Georgetown University, PI - Xuelin Huang, 1/1/2022-12/31/2025, $733,816 ($60,000/year)

Statistician, 3%, Olaparib in Combination with Futibatnib in All Solid Tumors with BRCA1/2, #TBA, Gateway for Cancer Research, PI - Jordi Rodon Ahnert, 3/1/2022-2/29/2024, $739,337 ($368,168/year)

Co-Investigator, 5%, Dietary magnesium replacement for prevention of hypomagnesemia in ovarian cancer patients receiving platinum-based chemotherapy, 1R21CA260162-01A1, NIH/NCI, PI - Wenli Liu, 4/1/2022-3/31/2024, $445,500 ($243,000/year)

Co-Investigator, 10%, Psycho-Spiritual Management for Patients with Advanced Cancer and their Spousal Caregivers, 1R01CA258640-01A1, NIH/NCI, PI - Kathrin Milbury, 4/1/2022-3/31/2027, $3,646,470 ($755,608/year)

Collaborator, 1%, Dietary magnesium and efficacy of vitamin D supplementation in patients with vitamin D deficiency and Hodgkin's lymphoma, #TBA, GABRIELLES ANGEL FDN FOR CANCER RESEARCH, PI - Wenli Liu, 5/1/2022-4/30/2025, $224,999 ($75,000/year)

Statistician, 1%, Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma, 1R21CA274090-01, NIH/NCI, PI - Isabella Glitza Oliva, 7/1/2022-6/30/2024, $275,000 ($150,000/year)

Co-Investigator, 15%, Simulation Modeling to Inform Clinical Translation of Emerging Breast Cancer Therapies, 1R01CA266441-01A1, NIH/NCI subaward via Georgetown University, PI - Young Chandler, 7/1/2022-6/30/2026, $400,000 ($100,000/year)

Co-Investigator, 5%, Biobehavioral Effects and Mechanisms of Tele-Health Delivery of Lifestyle Interventions for Overweight Women with Breast Cancer, 1R01CA266277-01A1, NIH/NCI, PI - Lorenzo Cohen, 7/1/2022-6/30/2027, $4,041,421 ($805,823/year)

Co-Investigator, 10%, Harmony & Health: A culturally adapted mind-body intervention to reduce sitting time in Black adults, 1R01CA272586-01, NIH/NCI, PI - Scherezade Mama, 7/1/2022-6/30/2027, $3,919,373 ($808,675/year)

Core Director, 12%, MD Anderson Epigenetics SPORE, 1P50CA261606-01A1, NIH/NCI, PI - Rai / Yee, 7/1/2022-6/30/2027, $11,318,808

Core Director, 10%, MD Anderson Sarcoma SPORE, 1P50CA272219-01, NIH/NCI, PI - Gorlick / Futreal, 7/1/2022-6/30/2027, $12,188,649

Co-Investigator, 5%, Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery, 1R01CA272565-01, NIH/NCI, PI - Lorenzo Cohen, 7/1/2022-6/30/2027, $3,937,602 ($802,844/year)

Co-Investigator, 5%, Supporting and Sustaining Behavior Change in Women at Risk for Breast Cancer Using a Comprehensive Mobile-Health Delivery Program, 1R01CA272750-01, NIH/NCI, PI - Lorenzo Cohen, 7/1/2022-6/30/2027, $4,043,914 ($809,598/year)

Co-Investigator, 15%, Simulation Modeling of Cancer Therapeutic Advances: A Tool to Translate Trial Results into Practice, 1R01CA276149-01, NIH subaward via Georgetown University Medical Center, PI - Young Chandler, 9/1/2022-8/31/2026, $647,997 ($161,999/year)

Co-Investigator, 1%, Improving quality of care using an AI-based nutrition expert platform (Ina®) delivered via SMS-text during breast cancer treatment, #TBA, Agency for Healthcare Research & Qual, PI - Gabriel Lopez, 9/1/2022-8/31/2027, $1,018,594 ($142,046/year)

Co-Investigator, 10%, Psycho-Spiritual Management for Patients with Advanced Cancer and their Family Caregivers, 1R01CA276035-01, NIH/NCI, PI - Kathrin Milbury, 9/1/2022-8/31/2027, $3,707,441 ($767,769/year)

Co-Investigator, Simulation Modeling to Inform Clinical Translation of the Emerging Breast Cancer Therapy, #TBA, American Cancer Society subaward via Georgetown University, PI - Young Chandler, 12/1/2022-11/30/2026, $240,001 ($50,000/year)

Co-Investigator, 5%, Harmony & Health: A culturally adapted mind-body intervention to reduce sitting time and improve psychosocial wellbeing in Black adults, #TBA, American Cancer Society (ACS), PI - Scherezade Mama, 1/1/2023-12/31/2026, $791,999 ($165,000/year)

Collaborator, 2%, Added sugar as a dietary rick factor for the progression of breast cancer, #TBA, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Peiying Yang, 3/1/2023-2/28/2026, $1,034,271 ($325,593/year)

Collaborator, 10%, Harmony & Health: A culturally adapted mind-body intervention to reduce cancer risk in Black adults in Texas, #TBA, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Scherezade Mama, 3/1/2023-2/29/2028, $1,684,558 ($337,613/year)

Co-Investigator, 6%, Harmony & Health: A culturally adapted mind-body intervention to reduce sitting time in Black adults, 1R01CA272586-01A1, NIH/NCI, PI - Scherezade Mama, 4/1/2023-3/31/2028, $3,166,694 ($389,023/year)

Co-Investigator, 5%, Supporting and Sustaining Behavior Change in Overweight Women with Breast Cancer: Biobehavioral Effects and Mechanisms of a Comprehensive Telehealth Lifestyle Intervention, 1R01CA280842-01, NIH/NCI, PI - Lorenzo Cohen, 4/1/2023-3/31/2028, $3,898,180 ($499,449/year)

Co-Investigator, 2%, Assessing Therapeutic Cancer Clinical Trial Perceptions and Enrollment Patterns at a Safety-Net Hospital – LBJ Hospital, #TBA, Conquer Cancer Foundation, PI - Cindy Pabon, 7/1/2023-6/30/2024, $49,999 ($47,499/year)

Co-Investigator, 5%, Exercise for Cancer Immune Interception in Lynch Syndrome Patients, 1R01CA284597-01, NIH/NCI, PI - Eduardo Vilar Sanchez, 7/1/2023-6/30/2028, $5,855,661 ($923,864/year)

Core Director, 12%, MD Anderson Epigenetics SPORE, 1P50CA281766-01, NIH/NCI, PI - Kunal Rai, 7/1/2023-6/30/2028, $11,339,672 ($1,399,974/year)

Collaborator, 5%, Persistent fatigue after curative treatment for breast cancer: is it a lack of energy?, #TBA, NIH/NCI, PI - Tamara Lacourt, 7/1/2023-6/30/2028, $2,906,089 ($396,127/year)

Co-Investigator, 5%, Persistent Fatigue in Young Adult Survivors of Breast Cancer: is it a lack of energy?, #TBA, American Cancer Society (ACS), PI - Tamara Lacourt, 1/1/2024-12/31/2027, $652,888 ($752,431/year)

Co-Investigator, 2%, Magnesium-rich dietary intervention to prevent hypomagnesemia in ovarian cancer patients undergoing platinum-based chemotherapy, #TBA, NIH/NCI, PI - Meroe Morse, 3/1/2024-2/28/2026, $445,500 ($125,000/year)

Co-Investigator, 5%, Epigenetically enhanced Endogenous T Cell Therapy for Pancreatic Cancer, #TBA, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Cassian Yee, 3/1/2024-2/9/2028, $1,993,155 ($472,750/year)

Collaborator, 1%, Measuring and Modulating Brain Function for Prevention of Neuropathy, #TBA, NATL INST OF NEURO DISORDERS AND STROKE, PI - Sarah Prinsloo, 4/1/2024-3/31/2026, $445,500 ($150,000/year)

Collaborator, 3%, The use of a botanical product to prevent radiation-induced lung injury: inflammatory and immunological mechanisms, #TBA, NIH/NCI, PI - Peiying Yang, 4/1/2024-3/31/2027, $1,215,000 ($250,000/year)

Collaborator, 10%, Persistent fatigue after curative treatment for breast cancer: is it a lack of energy?, #TBA, NIH/NCI, PI - Tamara Lacourt, 4/1/2024-3/31/2029, $4,417,689 ($558,351/year)

Co-Investigator, 5%, Persistent Fatigue in Young Adult Survivors of Breast Cancer: is it a lack of energy?, 1145256, American Cancer Society (ACS), PI - Tamara Lacourt, 7/1/2024-6/30/2028, $900,623 ($194,559/year)

Core C Lead, 10%, Novel Mitochondrial Mechanisms in AML, PAR-23-059, NIH/NCI, PI - Michael Andreeff, 7/1/2024-6/30/2029, $12,176,990 ($2,026,119/year)

**Protocols**

**Funded**

N/A

**Unfunded**

N/A

**Patents and Technology Licenses**

**Patents**

N/A

**Technology Licenses**

N/A

**Grant Reviewer/Service on Study Sections**

Center for Scientific Review Cancer Biomarkers Study Section Special Emphasis Panel, NIH, Member, 2009

Mathematics and Statistics Discovery Grant, NSERC of Canada, External Reviewer, 2015-2016

NIMHD Specialized Center of Excellence Special Emphasis Panel, NIH, Member, Reviewed NIMHD Specialized Centers of Excellence on Minority Health and Health Disparities (U54) Grants, 2017

Statistical Grant, Medical Research Council of the United Kingdom, External Reviewer, 2019

NIH/NINDS Special Emphasis Panel/Scientific Review Group 2020/10 ZNS1 SRB-G (32) Meeting, NIH, Member, Reviewed U01 Stroke Clinical Trials, 2020

Statistical Grant, Medical Research Council of the United Kingdom, External Reviewer, 2020

NIH/NINDS Special Emphasis Panel/Scientific Review Group 2021/10 ZNS1 SRB-G (42) Meeting, NIH, Member, Reviewed UG3/UH3 Stroke Clinical Trials, 2021

Statistical Grant, Round NWO Talent Programme 2021 - Behaviour and Education, Dutch Research Council, External Reviewer, Reviewed a Statistical Methodology Grant, 2021-2022

NIH/NINDS Special Emphasis Panel/Scientific Review Group 2022/05 ZNS1 SRB-G (48) Meeting, NIH, Member, Reviewed Stroke Clinical Trials, 2022

NIH/NINDS Special Emphasis Panel/Scientific Review Group 2022/10 ZNS1 SRB-W (01) Meeting, NIH, Member, Reviewed Stroke Clinical Trials, 2022

NIH/NINDS Special Emphasis Panel/Scientific Review Group 2023/05 ZNS1 SRB-W (10) Meeting, NIH, Member, Review Stroke Clinical Trials, 2023

NIH/NINDS Special Emphasis Panel/Scientific Review Group 2023/10 ZNS1 SRB-W (18) Meeting, NIH, Member, Review Stroke Clinical Trials, 2023

NIH/NINDS Special Emphasis Panel/Scientific Review Group 2024/05 ZNS1 SRB-W (22) Meeting, NIH, Member, 2024

NIH/NINDS Special Emphasis Panel/Scientific Review Group 2024/10 ZNS1 SRB-W (23) Meeting, NIH, Member, 2024

**PUBLICATIONS**

**Peer-Reviewed Original Research Articles**

1. Yin G, **Li Y**, Ji Y. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios. Biometrics 62(3):777-787, 2006. PMID: 16984320.
2. Wetter DW, Mazas C, Daza P, Nguyen L, Fouladi RT, **Li Y**, Cofta-Woerpel L. Reaching and treating Spanish-speaking smokers through the National Cancer Institute's Cancer Information Service: a randomized controlled trial. Cancer 109(2 suppl):406-13, 1/2007. PMID: 17149758.
3. Ji Y, **Li Y**, Yin G. Bayesian dose finding in phase I clinical trials based on a new statistical framework. Statistica Sinica 17(2):531-547, 4/2007. PMID: Not in PubMed.
4. Ji Y, **Li Y**, Nebiyou Bekele B. Dose-finding in phase I clinical trials based on toxicity probability intervals. Clinical Trials 4(3):235-44, 6/2007. PMID: 17715248.
5. Canada AL, Schover LR, **Li Y**. A pilot intervention to enhance psychosexual development in adolescents and young adults with cancer. Pediatric Blood and Cancer 6(49):824-8, 11/2007. PMID: 17226851.
6. Reitzel LR, Vidrine JI, **Li Y**, Mullen PD, Velasquez MM, Cinciripini PM, Cofta-Woerpel L, Greisinger A, Wetter DW. The influence of subjective social status on vulnerability to postpartum smoking among young pregnant women. American Journal of Public Health 97(8):1476-1482, 2007. PMCID: PMC1931465.
7. **Li Y**, Bekele BN, Ji Y, Cook JD. Dose-schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation. Statistics in Medicine 27(24):4895-913, 2008. PMCID: PMC4562497.
8. Waters AJ, **Li Y**. Evaluating the utility of administering a reaction time task in an ecological momentary assessment study. Psychopharmacology (Berl) 197(1):25-35, 2008. PMID: 18064440.
9. Kendzor DE, Costello TJ, **Li Y**, Vidrine JI, Mazas CA, Reitzel LR, Cinciripini PM, Cofta-Woerpel LM, Businelle MS, Wetter DW. Race/ethnicity and multiple cancer risk factors among individuals seeking smoking cessation treatment. Cancer Epidemiol Biomarkers Prev 17(11):2937-45, 2008. PMCID: PMC5013545.
10. Kendzor DE, Cofta-Woerpel LM, Mazas CA, **Li Y**, Vidrine JI, Reitzel LR, Costello TJ, Businelle MS, Ahluwalia JS, Cinciripini PM, Wetter DW. Socioeconomic status, negative affect, and modifiable cancer risk factors in African-American smokers. Cancer Epidemiol Biomarkers Prev 17(10):2546-54, 2008. PMCID: PMC2602870.
11. Leventhal AM, Waters AJ, Breitmeyer BG, Miller EK, Tapia E, **Li Y**. Subliminal processing of smoking-related and affective stimuli in tobacco addiction. Exp Clin Psychopharmacol 16(4):301-12, 2008. PMCID: PMC2677753.
12. Shinn EH, Taylor CL, Kilgore K, Valentine A, Bodurka DC, Kavanagh J, Sood A, **Li Y**, Basen-Engquist K. Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients. Palliat Support Care 7(3):299-306, 9/2009. PMCID: PMC3265166.
13. Waters AJ, Reitzel LR, Cinciripini PM, **Li Y**, Marcus M, Vidrine JI, Wetter DW. Associations between mindfulness and implicit cognition and self-reported affect. Subst Abus 30(4):328-337, Oct-Dec, 10/2009. PMCID: PMC5024533.
14. Vidrine JI, Businelle MS, Cinciripini PM, **Li Y**, Marcus M, Waters AJ, Wetter DW. Associations of mindfulness with nicotine dependence, withdrawal, and agency. Subst Abus 30(4):318-327, Oct-Dec, 10/2009. PMCID: PMC5038916.
15. Castro Y, Reitzel LR, Businelle MS, Kendzor DE, Mazas CA, **Li Y**, Cofta-Woerpel L, Wetter DW. Acculturation differentially predicts smoking cessation among Latino men and women. Cancer Epidemiol Biomarkers Prev 18(12):3468-3475, 12/2009. PMCID: PMC2798575.
16. Businelle MS, Kendzor DE, Costello TJ, Cofta-Woerpel L, **Li Y**, Mazas CA, Vidrine JI, Reitzel LR, Cinciripini PM, Ahluwalia JS, Wetter DW. Light versus heavy smoking among African-American men and women. Addict Behav 34(2):197-203, 2009. PMCID: PMC2614080.
17. Reitzel LR, Costello TJ, Mazas CA, Vidrine JI, Businelle MS, Kendzor DE, **Li Y**, Cofta-Woerpel L, Wetter DW. Low-level smoking among Spanish-speaking Latino smokers: Relationships with demographics, tobacco dependence, withdrawal, and cessation. Nicotine Tob Res 11(2):178-84, 2009. PMCID: PMC2658909.
18. Kendzor DE, Businelle MS, Mazas CA, Cofta-Woerpel LM, Reitzel LR, Vidrine JI, **Li Y**, Costello TJ, Cinciripini PM, Ahluwalia JS, Wetter DW. Pathways between socioeconomic status and modifiable risk factors among African American smokers. J Behav Med 32(6):545-557, 2009. PMCID: PMC2828046.
19. Huang X, Ning J, **Li Y**, Estey E, Issa J-P, Berry DA. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Statistics in Medicine 28(12):1680-1689, 2009. PMCID: PMC2883264.
20. **Li Y**, Lin X, Müller P. Bayesian inference in semiparametric mixed models for longitudinal data. Biometrics 66(1):70-78, 3/2010. PMCID: PMC3081790.
21. Kendzor DE, Businelle MS, Costello TJ, Castro Y, Reitzel LR, Cofta-Woerpel LM, **Li Y**, Mazas CA, Vidrine JI, Cinciripini PM, Greisinger AJ, Wetter DW. Financial strain and smoking cessation among racially/ethnically diverse smokers. Am J Public Health 100(4):702-706, 4/2010. PMCID: PMC2836332.
22. Reitzel LR, Vidrine JI, Businelle MS, Kendzor DE, Costello TJ, **Li Y**, Daza P, Mullen PD, Velasquez MM, Cinciripini PM, Cofta-Woerpel L, Wetter DW. Preventing postpartum smoking relapse among diverse, low income women: A randomized clinical trial. Nicotine Tob Res 12(4):326-35, 4/2010. PMCID: PMC2847071.
23. Businelle MS, Kendzor DE, Reitzel LR, Costello TJ, Cofta-Woerpel L, **Li Y**, Mazas CA, Vidrine JI, Cinciripini PM, Greisinger AJ, Wetter DW. Mechanisms linking socioeconomic status to smoking cessation: A structural equation modeling approach. Health Psychol 29(3):262-73, 5/2010. PMCID: PMC2922845.
24. Reitzel LR, Mazas CA, Cofta-Woerpel L, **Li Y**, Cao Y, Businelle MS, Cinciripini PM, Wetter DW. Subjective social status affects smoking abstinence during acute withdrawal through affective mediators. Addiction 105(5):928-36, 5/2010. PMCID: PMC2857594.
25. Bekele BN, **Li Y**, Ji Y. Risk-group-specific dose finding based on an average toxicity score. Biometrics 66(2):541-548, 6/2010. PMCID: PMC4570736.
26. Vidrine JI, Rabius V, Alford MH, **Li Y**, Wetter DW. Enhancing dissemination of smoking cessation quitlines through T2 translational research: A unique partnership to address disparities in the delivery of effective cessation treatment. J Public Health Manag Pract 16(4):304-308, Jul-Aug, 7/2010. PMCID: PMC4023535.
27. Kendzor DE, Businelle MS, Costello TJ, Castro Y, Reitzel LR, Vidrine JI, **Li Y**, Mullen PD, Velasquez MM, Cinciripini PM, Cofta-Woerpel LM, Wetter DW. Breast feeding is associated with postpartum smoking abstinence among women who quit smoking due to pregnancy. Nicotine Tob Res 12(10):983-8, 10/2010. PMCID: PMC2948049.
28. Ji Y, Liu P, **Li Y**, Bekele BN. A modified toxicity probability interval method for dose-finding trials. Clin Trials 7(6):653-663, 12/2010. PMCID: PMC5038924.
29. Reitzel LR, Mazas CA, Cofta-Woerpel L, Vidrine JI, Businelle MS, Kendzor DE, **Li Y**, Wetter DW. Acculturative and neighborhood influences on subjective social status among Spanish-speaking Latino immigrant smokers. Soc Sci Med 70(5):677-83, Mar, 2010. PMCID: PMC5048887.
30. Waters AJ, Miller EK, **Li Y**. Administering the implicit association test in an ecological momentary assessment study. Psychological Reports 106(1):31-43, 2010. PMID: 20402424.
31. **Li Y**, Müller P, Lin X. Center-adjusted inference for a nonparametric Bayesian random effect distribution. Statistica Sinica 21(3):1201-1223, 7/2011. PMCID: PMC3870168.
32. Reitzel LR, McClure JB, Cofta-Woerpel L, Mazas CA, Cao Y, Cinciripini PM, Vidrine JI, **Li Y**, Wetter DW. The efficacy of computer-delivered treatment for smoking cessation. Cancer Epidemiol Biomarkers Prev 20(7):1555-1557, 7/2011. PMCID: PMC3132322.
33. Cofta-Woerpel L, McClure JB, **Li Y**, Urbauer D, Cinciripini PM, Wetter DW. Early cessation success or failure among women attempting to quit smoking: trajectories and volatility of urge and negative mood during the first postcessation week. J Abnorm Psychol 120(3):596-606, 8/2011. PMCID: PMC3153568.
34. Hsu C-H, **Li Y**, Long Q, Zhao Q, Lance P. Estimation of recurrence of colorectal adenomas with dependent censoring using weighted logistic regression. PLoS One 6(10):e25141, 10/2011. PMCID: PMC3204965.
35. Heppner WL, Ji L, Reitzel LR, Reitzel L, Castro Y, Correa-Fernandez V, Vidrine JI, **Li Y**, Dolan-Mullen P, Velasquez MM, Cinciripini PM, Cinciripini P, Cofta-Woerpel L, Cofta-Woerpel L, Greisinger A, Wetter D. The role of prepartum motivation in the maintenance of postpartum smoking abstinence. Health Psychol 30(6):736-45, 11/2011. PMCID: PMC3221324.
36. Reitzel LR, Nguyen N, Cao Y, Vidrine JI, Daza P, Mullen PD, Velasquez MM, **Li Y**, Cinciripini PM, Cofta-Woerpel L, Wetter DW. Race/ethnicity moderates the effect of prepartum menthol cigarette use on postpartum smoking abstinence. Nicotine Tob Res 13(12):1305-1310, 12/2011. PMCID: PMC3223573.
37. Reitzel LR, Businelle MS, Kendzor DE, **Li Y**, Cao Y, Castro Y, Mazas CA, Cofta-Woerpel L, Cinciripini PM, Wetter DW. Subjective social status predicts long-term smoking abstinence. BMC Public Health 11:135, 2011. PMCID: PMC3050754.
38. Reitzel LR, Cromley EK, **Li Y**, Cao Y, Dela Mater R, Mazas CA, Cofta-Woerpel L, Cinciripini PM, Wetter DW. The effect of tobacco outlet density and proximity on smoking cessation. American Journal of Public Health 101(2):315-320, 2011. PMCID: PMC3020198.
39. Waters AJ, Burgess A, Hughes DL, Jovanovic JL, Miller EK, **Li Y**, Basen-Engquist KM. Outcome expectancies and expectancy accessibility in exercise behavior. Journal of Applied Social Psychology 42(2):414-439, 2/2012.
40. Parker PA, Swartz R, Fellman B, Urbauer D, **Li Y**, Pisters LL, Rosser CJ, Wood CG, Matin SF. Comprehensive assessment of quality of life and psychosocial adjustment in patients with renal tumors undergoing different surgical procedures. J Urol 187(3):822-826, 3/2012. PMCID: PMC3866893.
41. Kendzor DE, Reitzel LR, Mazas CA, Cofta-Woerpel LM, Cao Y, Ji L, Costello TJ, Vidrine JI, Businelle MS, **Li Y**, Castro Y, Ahluwalia JS, Cinciripini PM, Wetter DW. Individual- and area-level unemployment influence smoking cessation among African Americans participating in a randomized clinical trial. Soc Sci Med 74(9):1394-401, 5/2012. PMCID: PMC3321106.
42. Reitzel LR, Vidrine JI, Businelle MS, Kendzor DE, Cao Y, Mazas CA, **Li Y**, Ahluwalia JS, Cinciripini PM, Cofta-Woerpel L, Wetter DW. Neighborhood perceptions are associated with tobacco dependence among African American smokers. Nicotine Tob Res 14(7):786-793, 7/2012. PMCID: PMC3390547.
43. Sofuoglu M, Herman AI, **Li Y**, Waters AJ. Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report. Psychopharmacology (Berl) 224(3):413-20, 12/2012. PMCID: PMC3636552.
44. Long Q, Hsu CH, **Li Y**. Doubly robust nonparametric multiple imputation for ignorable missing data. Statistica Sinica 22(1):149-172, 2012. PMCID: PMC3280694.
45. Reitzel LR, Kendzor DE, Castro Y, Cao Y, Businelle MS, Mazas CA, Cofta-Woerpel L, **Li Y**, Cinciripini PM, Ahluwalia JS, Wetter DW. The relation between social cohesion and smoking cessation among black smokers, and the potential role of psychosocial mediators. Ann Behav Med 45(2):249-57, 4/2013. PMCID: PMC3587036.
46. Reitzel LR, Lahoti S, **Li Y**, Cao Y, Wetter DW, Waters AJ, Vidrine JI. Neighborhood vigilance, health locus of control, and smoking abstinence. Am J Health Behav 37(3):334-341, 5/2013. PMCID: PMC3761415.
47. Reitzel LR, **Li Y**, Stewart DW, Cao Y, Wetter DW, Waters AJ, Vidrine JI. Race moderates the effect of menthol cigarette use on short-term smoking abstinence. Nicotine Tob Res 15(5):883-9, 5/2013. PMCID: PMC3621585.
48. Parker PA, Alba F, Fellman B, Urbauer DL, **Li Y**, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol 63(6):1122–7, 6/2013. PMCID: PMC3866912.
49. Stewart DW, Adams CE, Cano MA, Correa-Fernández V, **Li Y**, Waters AJ, Wetter DW, Vidrine JI. Associations between health literacy and established predictors of smoking cessation. Am J Public Health 103(7):e43-9, 7/2013. PMCID: PMC3682601.
50. Basen-Engquist K, Carmack CL, **Li Y**, Brown J, Jhingran A, Hughes DC, Perkins HY, Scruggs S, Harrison C, Baum G, Bodurka DC, Waters A. Social cognitive theory predictors of exercise behavior in endometrial cancer survivors. Health Psychol 32(11):1137-48, 11/2013. PMCID: PMC4057057.
51. Vidrine JI, Shete S, **Li Y**, Cao Y, Alford MH, Galindo-Talton M, Rabius V, Sharp B, Harmonson P, Zbikowski SM, Miles L, Wetter DW. The ask-advise-connect approach for smokers in a safety net healthcare system: a group-randomized trial. Am J Prev Med 45(6):737-41, 12/2013. PMCID: PMC4023543.
52. Castro Y, Basen-Engquist K, Fernandez ME, Strong LL, Eakin EG, Resnicow K, **Li Y**, Wetter DW. Design of a randomized controlled trial for multiple cancer risk behaviors among Spanish-speaking Mexican-origin smokers. BMC Public Health 13:237, 2013. PMCID: PMC3610197.
53. Hsu C-H, Long Q, **Li Y**, Jacobs B. A nonparametric multiple imputation approach for data with missing covariate values with application to colorectal adenoma data. Journal of Biopharmaceutical Statistics 24(3):634-648, 4/2014. PMCID: PMC4353564.
54. Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, **Li Y**, Cantley LC, Winer E, Arteaga CL. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 32(12):1202-9, 4/2014. PMCID: PMC3986383.
55. Waters AJ, Szeto EH, Wetter DW, Cinciripini PM, Robinson JD, **Li Y**. Cognition and craving during smoking cessation: An ecological momentary assessment study. Nicotine Tob Res 16(Suppl 2):S111-S118, 5/2014. PMCID: PMC3977632.
56. Adams CE, Chen M, Guo L, Lam CY, Stewart DW, Correa-Fernández V, Cano MA, Heppner WL, Vidrine JI, **Li Y**, Ahluwalia JS, Cinciripini PM, Wetter DW. Mindfulness predicts lower affective volatility among African Americans during smoking cessation. Psychol Addict Behav 28(2):580-5, 6/2014. PMCID: PMC4096677.
57. Stewart DW, Cano MA, Correa-Fernández V, Spears CA, **Li Y**, Waters AJ, Wetter DW, Vidrine JI. Lower health literacy predicts smoking relapse among racially/ethnically diverse smokers with low socioeconomic status. BMC Public Health 14:716, 7/2014. PMCID: PMC4226955.
58. Rogith D, Yusuf RA, Hovick SR, Peterson SK, Burton-Chase AM, **Li Y**, Meric-Bernstam F, Bernstam EV. Attitudes regarding privacy of genomic information in personalized cancer therapy. J Am Med Inform Assoc 21(e2):e320-e325, 10/2014. PMCID: PMC4173182.
59. Stewart DW, Reitzel LR, Correa-Fernández V, Cano MÁ, Adams CE, Cao Y, **Li Y**, Waters AJ, Wetter DW, Vidrine JI. Social support mediates the association of health literacy and depression among racially/ethnically diverse smokers with low socioeconomic status. J Behav Med 37(6):1169-79, 12/2014. PMCID: PMC4231826.
60. \*Guo B, **Li Y**. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship. BMC Med Res Methodol 14:95, 2014. PMCID: PMC4119476.
61. Vidrine DJ, Fletcher FE, Buchberg MK, **Li Y**, Arduino RC, Gritz ER. The influence of HIV disease events/stages on smoking attitudes and behaviors: Project STATE (Study of Tobacco Attitudes and Teachable Events). BMC Public Health 14:149, 2014. PMCID: PMC3929124.
62. Yusuf RA, Rogith D, Hovick SR, Peterson SK, Burton-Chase AM, Fellman BM, **Li Y**, McKinney C, Bernstam EV, Meric-Bernstam F. Attitudes toward molecular testing for personalized cancer therapy. Cancer 121(2):243-50, 1/2015. PMCID: PMC4293219.
63. \*Guo B, **Li Y**. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering. Stat Med 34(5):859-875, 2/2015. PMCID: PMC4359011.
64. González-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, **Li Y**, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst 107(3):dju493, 3/2015. PMCID: PMC4342675.
65. Adams CE, Cano MA, Heppner WL, Stewart DW, Correa-Fernández V, Vidrine JI, **Li Y**, Cinciripini PM, Ahluwalia JS, Wetter DW. Testing a moderated mediation model of mindfulness, psychosocial stress, and alcohol use among African American smokers. Mindfulness (N Y) 6(2):315-325, 4/2015. PMCID: PMC4384702.
66. Vidrine JI, Businelle MS, Reitzel LR, Cao Y, Cinciripini PM, Marcus MT, **Li Y**, Wetter DW. Coping mediates the association of mindfulness with stress, affect and depression among smokers preparing to quit. Mindfulness 6(3):433-443, 6/2015. PMCID: PMC5296771.
67. Robinson CD, Pickworth WB, Heishman SJ, Wetter DW, Cinciripini PM, **Li Y**, Rowell B, Waters AJ. Black cigarette smokers report more attention to smoking cues than White smokers: Implications for smoking cessation. Nicotine Tob Res 17(8):1022-8, 8/2015. PMCID: PMC4838045.
68. Holder AM, Akcakanat A, Adkins F, Evans K, Chen H, Wei C, Milton DR, **Li Y**, Do KA, Janku F, Meric-Bernstam F. Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget 6(23):19500-13, 8/2015. PMCID: PMC4637301.
69. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, **Li Y**, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol 33(25):2753-62, 9/2015. PMCID: PMC4550690.
70. Hall CS, Karhade M, Laubacher BA, Kuerer HM, Krishnamurthy S, DeSnyder S, Anderson AE, Valero V, Ueno NT, **Li Y**, Su X, Lucci A. Circulating tumor cells and recurrence after primary systemic therapy in stage III inflammatory breast cancer. J Natl Cancer Inst 107(11):djv250, 11/2015. PMCID: PMC4849361.
71. Garcia MK, Graham-Getty L, Haddad R, **Li Y**, McQuade J, Lee RT, Spano M, Cohen L. Systematic review of acupuncture to control hot flashes in cancer patients. Cancer 121(22):3948-58, 11/2015. PMCID: PMC4635055.
72. \*Guo B, **Li Y**, Yuan Y. A dose-schedule-finding design for phase I/II clinical trials. J R Stat Soc Ser C Appl Stat 65(2):259-272, 2/2016. PMCID: PMC4747255.
73. Rogith D, Yusuf RA, Hovick SR, Fellman BM, Peterson SK, Burton-Chase AM, **Li Y**, Bernstam EV, Meric-Bernstam F. Patient knowledge and information-seeking about personalized cancer therapy. Int J Med Inform 88:52-57, 4/2016. PMCID: PMC4789765.
74. Mama SK, **Li Y**, Basen-Engquist K, Lee RE, Thompson D, Wetter DW, Nguyen NT, Reitzel LR, McNeill LH. Psychosocial mechanisms linking the social environment to mental health in African Americans. PLoS One 11(4):e0154035, 4/2016. PMCID: PMC4847864.
75. Hsu CH, He Y, **Li Y**, Long Q, Friese R. Doubly robust multiple imputation using kernel-based techniques. Biom J 58(3):588-606, 5/2016. PMCID: PMC5167998.
76. Heppner WL, Spears CA, Correa-Fernández V, Castro Y, **Li Y**, Guo B, Reitzel LR, Vidrine JI, Mazas CA, Cofta-Woerpel L, Cinciripini PM, Ahluwalia JS, Wetter DW. Dispositional mindfulness predicts enhanced smoking cessation and smoking lapse recovery. Ann Behav Med 50(3):337-347, 6/2016. PMCID: PMC4867253.
77. Vidrine JI, Spears CA, Heppner WL, Reitzel LR, Marcus MT, Cinciripini PM, Waters AJ, **Li Y**, Nguyen NT, Cao Y, Tindle HA, Fine M, Safranek LV, Wetter DW. Efficacy of mindfulness-based addiction treatment (MBAT) for smoking cessation and lapse recovery: A randomized clinical trial. J Consult Clin Psychol 84(9):824-838, 9/2016. PMCID: PMC5061584.
78. Endrighi R, Waters AJ, Gottlieb SS, Harris KM, Wawrzyniak AJ, Bekkouche NS, **Li Y**, Kop WJ, Krantz DS. Psychological stress and short-term hospitalisations or death in patients with heart failure. Heart 102(22):1820-25, 2016. PMCID: PMC5237617.
79. Correa-Fernández V, Díaz-Toro EC, Reitzel LR, Guo L, Chen M, **Li Y**, Calo WA, Shih YT, Wetter DW. Combined treatment for at-risk drinking and smoking cessation among Puerto Ricans: A randomized clinical trial. Addict Behav 65:185-192, 2/2017. PMCID: PMC5358923.
80. Arun B, Austin T, Babiera GV, Basen-Engquist K, Carmack CL, Chaoul A, Cohen L, Connelly L, Haddad R, Harrison C, **Li Y**, Mallaiah S, Nagarathna R, Parker PA, Perkins GH, Reuben JM, Shih YT, Spelman A, Sood A, Yang P, Yeung SJ. A comprehensive lifestyle randomized clinical trial: Design and initial patient experience. Integr Cancer Ther 1(16):3-20, 3/2017. PMCID: PMC5558265.
81. Cox M, Basen-Engquist K, Carmack CL, Blalock J, **Li Y**, Murray J, Pisters L, Rodriguez-Bigas M, Song J, Cox-Martin E, Demark-Wahnefried W. Comparison of internet and telephone interventions for weight loss among cancer survivors: Randomized controlled trial and feasibility study. JMIR Cancer 3(2):e16, 9/2017. PMCID: PMC5637068.
82. Mayer IA, Abramson V, Formisano L, Balko JM, Estrada MV, Sanders M, Juric D, Solit D, Berger MF, Won H, **Li Y**, Cantley LC, Winer EP, Arteaga CL. A SU2C phase Ib study of alpelisib (BYL719, a PI3Kα-specific inhibitor) with letrozole in ER+/HER2-negative metastatic breast cancer. Clin Cancer Res 23(1):26-34, 2017. PMCID: PMC5085926.
83. Lopez G, Liu W, McQuade J, Lee RT, Spelman AR, Fellman B, **Li Y**, Bruera E, Cohen L. Integrative oncology outpatient consultations: long-term effects on patient-reported symptoms and quality of life. J Cancer 8(9):1640-1646, 2017. PMCID: PMC5535719.
84. Lopez G, McQuade J, Cohen L, Williams JT, Spelman AR, Fellman B, **Li Y**, Bruera E, Lee RT. Integrative oncology physician consultations at a comprehensive cancer center: analysis of demographic, clinical and patient reported outcomes. J Cancer 8(3):395-402, 2017. PMCID: PMC5332890.
85. Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, **Li Y**, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS. Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012. JAMA 319(2):154-164, 1/2018. PMCID: PMC5833658.
86. Pena I, Clayman GL, Grubbs EG, Bergeron JM, Waguespack SG, Cabanillas ME, Dadu R, Hu MI, Fellman BM, **Li Y**, Gross ND, Lai SY, Sturgis EM, Zafereo ME. Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head Neck 40(1):79-85, 1/2018. PMID: 29044788.
87. Chaoul A, Milbury K, Spelman A, Basen-Engquist K, Hall MH, Wei Q, Shih YT, Arun B, Valero V, Perkins GH, Babiera GV, Wangyal T, Engle R, Harrison CA, **Li Y**, Cohen L. Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy. Cancer 124(1):36-45, 1/2018. PMCID: PMC5735004.
88. Hoover DS, Wetter DW, Vidrine DJ, Nguyen N, Frank SG, **Li Y**, Waters AJ, Meade CD, Vidrine JI. Enhancing smoking risk communications: The influence of health literacy and message content. Ann Behav Med 52(3):204-215, 2/2018. PMCID: PMC5942894.
89. Kim C, Daniels M, **Li Y**, Milbury K, Cohen L. A Bayesian semiparametric latent variable approach to causal mediation. Stat Med 37(7):1149-1161, 3/2018. PMCID: PMC5837944.
90. Huang X, **Li Y**, Song J, Berry DA. A Bayesian simulation model for breast cancer screening, incidence, treatment, and mortality. Med Decis Making 38(1\_suppl):78S-88S, 4/2018. PMCID: PMC5711634.
91. Lopez G, Liu W, Madden K, Fellman B, **Li Y**, Bruera E. Adolescent-young adults (AYA) with cancer seeking integrative oncology consultations: Demographics, characteristics, and self-reported outcomes. Support Care Cancer 26(4):1161-1167, 4/2018. PMID: 29082436.
92. van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, **Li Y**, Alagoz O, Lee SJ, Stout NK, Song J, Trentham-Dietz A, Plevritis SK, Moss SM, de Koning HJ. Comparing CISNET breast cancer incidence and mortality predictions to observed clinical trial results of mammography screening from ages 40 to 49. Med Decis Making 38(1\_suppl):140S-150S, 4/2018. PMCID: PMC5862071.
93. van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, **Li Y**, Munoz DF, Plevritis SK, de Koning HJ, Stout NK, van Ballegooijen M. Comparing CISNET breast cancer models using the Maximum Clinical Incidence Reduction methodology. Med Decis Making 38(1\_suppl):112S-125S, 4/2018. PMCID: PMC5862068.
94. Prinsloo S, Novy D, Driver L, Lyle R, Ramondetta L, Eng C, Lopez G, **Li Y**, Cohen L. The long-term impact of neurofeedback on symptom burden and interference in patients with chronic chemotherapy-induced neuropathy: Analysis of a randomized controlled trial. J Pain Symptom Manage 55(5):1276-1285, 5/2018. PMID: 29421164.
95. Vidrine DJ, Frank SG, Savin MJ, Waters AJ, **Li Y**, Chen S, Fletcher FE, Arduino RC, Gritz ER. HIV care initiation: A teachable moment for smoking cessation? Nicotine Tob Res 20(9):1109-1116, 8/2018. PMCID: PMC6093446.
96. Lopez G, Garcia MK, Liu W, Spano M, Underwood S, Dibaj SS, **Li Y**, Moguel R, Williams J, Bruera E, Cohen L. Outpatient acupuncture effects on patient self-reported symptoms in oncology care: a retrospective analysis. Journal of Cancer 9(29):3613-3619, 9/2018. PMCID: PMC6171034.
97. Tam S, Boonsripitayanon M, Amit M, Fellman BM, **Li Y**, Busaidy N, Cabanillas M, Dadu R, Sherman SI, Waguespack SG, Williams MD, Goepfert RP, Gross ND, Perrier N, Sturgis E, Zafereo M. Survival in differentiated thyroid cancer: Comparing the AJCC cancer staging 7th and 8th editions. Thyroid 28(10):1301-1310, 10/2018. PMID: 30141373.
98. Jayasekera J, Schechter CB, Sparano JA, Jagsi R, White J, Chapman JW, Whelan T, Anderson SJ, Fyles AW, Sauerbrei W, Zellars RC, **Li Y**, Song J, Huang X, Julian TB, Luta G, Berry DA, Feuer EJ, Mandelblatt J, CISNET-BOLD Collaborative Group. Effects of radiotherapy in early-stage, low-recurrence risk, hormone-sensitive breast cancer. J Natl Cancer Inst 110(12):1370-1379, 12/2018. PMCID: PMC6292790.
99. Jayasekera J, **Li Y**, Schechter CB, Jagsi R, Song J, White J, Luta G, Chapman JW, Feuer EJ, Zellars RC, Stout N, Julian TB, Whelan T, Huang X, Shelley Hwang E, Hopkins JO, Sparano JA, Anderson SJ, Fyles AW, Gray R, Sauerbrei W, Mandelblatt J, Berry DA, CISNET-BOLD Collaborative Group. Simulation modeling of cancer clinical trials: Application to omitting radiotherapy in low-risk breast cancer. J Natl Cancer Inst 110(12):1360-1369, 12/2018. PMCID: PMC6292816.
100. Lopez G, Milbury K, Chen M, **Li Y**, Bruera E, Cohen L. Couples symptom burden in oncology care: Perception of self and the other. Support Care Cancer 27(1):139-145, 1/2019. PMCID: PMC6405284.
101. Milbury K, Liao Z, Shannon V, Mallaiah S, Raghuram N, **Li Y**, Yang C, Carmack C, Bruera, E, Cohen L. Dyadic yoga program for patients undergoing thoracic radiotherapy and their family caregivers: Results of a pilot randomized controlled trial. Psycho-Oncology 28(3):615-621, 3/2019. PMCID: PMC6405285.
102. Robertson MC, Lyons EJ, Song J, Cox-Martin M, **Li Y**, Green CE; Pinto B, Carmack C, Harrison C, Baum G, Basen-Engquist K. Change in physical activity and quality of life in endometrial cancer survivors receiving a physical activity intervention. Health and Quality of Life Outcomes 17(1):91, 5/2019. PMCID: PMC6537149.
103. Hoover DS, Spears CA, Vidrine DJ, Walker JL, Shih Y-C T, Wetter DW, Elting LS, Ramondetta LM, **Li Y**, Gillaspy SR, Vidrine JI. Smoking cessation treatment needs of low SES cervical cancer survivors. American Journal of Health Behavior 43(3):606-620, 5/2019. PMCID: PMC6686858.
104. Park K-U, Kuerer HM, Rauch GM, Leung JWT, Sahin AA, Wei W, **Li Y**, Black DM. Digital breast tomosynthesis for intra-operative margin assessment during breast conserving surgery. Annals of Surgical Oncology 26(6):1720-1728, 6/2019. PMID: 30877499.
105. Milbury K, Li J, Weathers S-P, Mallaiah S, Armstrong T, **Li Y**, Bruera E, Cohen L. Pilot randomized, controlled trial of a dyadic yoga program for glioma patients undergoing radiotherapy and their family caregivers. Neuro-Oncology Practice 6(4):311-320, 6/2019. PMCID: PMC6660820.
106. Milbury K, Li J, Weathers S-P, Shih T, Malliaha S, **Li Y**, Cohen L. A research protocol for a pilot, randomized controlled trial designed to examine the feasibility of a dyadic versus individual yoga program for family caregivers of glioma patients undergoing radiotherapy. Pilot and Feasibility Studies 5(95), 7/2019. PMCID: PMC6657047.
107. Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, **Li Y**, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res 21(1):78, 7/2019. PMCID: PMC6612080.
108. Hernandez M, Hernández-Valero MA, García-Prieto C, Patterson DG, Hajek RA, Recinos I, Lopez DS, **Li Y**, Jones LA, Hawk E. A pilot study evaluating organochlorine and organophosphate pesticide exposure in children and adolescents of Mexican descent residing in Hidalgo County, Texas. J Immigr Minor Health 21(4):751-760, 8/2019. PMID: 30066057.
109. Coletta AM, Klopp AH, Fogelman D, Parikh AM, **Li Y**, Garg N, Basen-Engquist K. Dual-Energy X-Ray Absorptiometry Compared to Computed Tomography for Visceral Adiposity Assessment Among Gastrointestinal and Pancreatic Cancer Survivors. Sci Rep 9(1):11500, 8/2019. PMCID: PMC6687706.
110. Stevens EM, Vidrine DJ, Hoover DS, Wetter DW, Frank SG, Nguyen N, **Li Y**, Waters AJ, Meade CD, Wagener T, Vidrine JI. Enhancing smoking risk communications: The influence of need for cognition. American Journal of Health Behavior 43(5):950-962, 9/2019. PMCID: PMC7045173.
111. Coletta AM, Brewster AM, Chen M, **Li Y**, Bevers TB, Basen-Engquist K, Gilchrist SC. High-intensity interval training is feasible in women at high risk for breast cancer. Medicine & Science in Sports & Exercise 51(11):2193-2200, 11/2019. PMCID: PMC7028472.
112. Lopez G, Eddy C, Liu W, **Li Y**, Chen M, Bruera E, Cohen L. Physical therapist-led exercise assessment and counseling in integrative cancer care: effects on patient self-reported symptoms and quality of life. Integrative Cancer Therapies 18:1534735419832360, 2019. PMCID: PMC6416745.
113. Murthy RK, Song J, Raghavendra AS, **Li Y**, Hsu L, Hess KR, Barcenas CH, Valero V, Carlson RW, Tripathy D, Hortobagyi GN. Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. NPJ Breast Cancer 6:11, 3/2020. PMCID: PMC7096449.
114. Milbury K, Weathers S-P, Durrani S, **Li Y**, Whisenant M, Li J, Lim B, Weinberg JS, Kesler S, Bruera E. Online couple-based meditation intervention for patients with primary or metastatic brain tumors and their partners: Results of a pilot randomized controlled trial. Journal of Pain and Symptom Management 59(6):1260-1267, 6/2020. PMID: 32061834.
115. Mama SK, Bhuiyan N, Chaoul A, Cohen L, Fagundes C, Hoover DS, Strong LL, **Li Y**, Nguyen NT, McNeill LH. Feasibility and acceptability of a faith-based mind-body intervention among African American adults. Translational Behavioral Medicine 10(4):928-937, 10/2020. PMCID: PMC7753004.
116. Milbury K, **Li Y**, Durrani S, Liao Z, Tsao AS, Carmack C, Cohen L, Bruera E. A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and Their Spouses: Results of a Three-Arm Pilot Randomized Controlled Trial. Oncologist 25(11):e1794-e1802, 11/2020. PMCID: PMC7648356.
117. Cho D, Basen-Engquist K, Acquati C, Pettaway C, Ma H, Markofski M, **Li Y**, Canfield SE, Gregg J, McNeill LH. Cultural adaptation of evidence-based lifestyle interventions for African American men with prostate cancer: A dyadic approach. American Journal of Men's Health 14(6):1557988320945449, 11/2020. PMCID: PMC7653295.
118. Lopez G, Narayanan S, Christie A, Powers-James C, Liu W, Garcia K, Gomez T, Wu J, Chunduru A, Williams J, **Li Y**, Bruera E, Cohen L. Effects of center-based delivery of Tai Chi and Qi Gong group classes on self-reported symptoms in cancer patients and caregivers. Integrative Cancer Therapies 19:1534735420941605, 11/2020. PMCID: PMC7374530.
119. Garrido-Castro AC, Saura C, Barroso-Sousa R, Guo H, Ciruelos E, Bermejo B, Gavilá J, Serra V, Prat A, Paré L, Céliz P, Villagrasa P, **Li Y**, Savoie J, Xu Z, Arteaga CL, Krop IE, Solit DB, Mills GB, Cantley LC, Winer EP, Lin NU, Rodon J. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res 22(1):120, 11/2020. PMCID: PMC7607628.
120. Basen-Engquist KM, Raber M, Carmack CL, Arun B, Brewster AM, Fingeret M, Schembre SM, Harrison C, Perkins HY, **Li Y**, Song J, Chen M, Murray JL. Feasibility and efficacy of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy: A randomized controlled pilot study. Supportive Care in Cancer 28(12):5821-5832, 12/2020. PMID: 32249355.
121. Chi WJ, Myers JN, Frank SJ, Aponte-Wesson RA, Otun AO, Nogueras-González GM, **Li Y**, Geng Y, Chambers MS. The effects of zinc on radiation-induced dysgeusia: A systematic review and meta-analysis. Support Care Cancer 28(12):1-12, 12/2020. PMID: 32642950.
122. Cho D, Basen-Engquist K, Acquati C, Ma H, Pettaway C, **Li Y**, McNeill LH. Study Protocol: A lifestyle intervention for African American and Hispanic prostate cancer survivors on active surveillance and their partners. Pilot and Feasibility Studies 6:111, 2020. PMCID: PMC7414583.
123. Narayanan S, Lopez G, Powers-James C, Fellman B, Chunduru A, **Li Y**, Bruera E, Cohen L. Integrative oncology consultations delivered via telehealth in 2020 and in-person in 2019: Paradigm shift during the COVID-19 world pandemic. Integrative Cancer Therapies 20:1534735421999101, 1/2021. PMCID: PMC7934055.
124. Prinsloo S, Vallone V, Moreno N, Sanchez H, Burgess H, Ike S, Novy D, Barcenas C, **Li Y**, Lopez G, Bruera E, Cohen L. Patient experiences of neurofeedback for chemotherapy-induced peripheral neuropathy: A case series comparing real and placebo treatment. Austin Neurosurgery: Open Access 7(1):1063, 3/2021.
125. Parker NH, Basen-Engquist K, Rubin ML, **Li Y**, Prakash L, Ngo-Huang A, Gorzelitz J, Ikoma N, Lee JE, Katz MHG. Factors influencing exercise following pancreatic tumor resection. Ann Surg Oncol 28(4):2299-2309, 4/2021. PMID: 32886288.
126. Srivastava A, Nogueras Gonzalez G, Weber D, Geng Y, Won AM, Cabanillas Maria E, Naing A, Myers J, **Li Y**, Chambers M. Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Supportive Care in Cancer 29(5):2305-2317, 5/2021. PMID: 33190182.
127. Barcenas CH, Song J, Murthy RK, Raghavendra AS, **Li Y**, Hsu L, Carlson RW, Tripathy D, Hortobagyi GN. Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer. JCO Clin Cancer Inform 5:789-804, 8/2021. PMCID: PMC8807018.
128. Cho D, Milbury K, Liao Y, Pettaway CA, Gregg JR, **Li Y**, McNeill LH. Study protocol: One plus one can be greater than two -- Ecological momentary assessment for Black prostate cancer survivors and partners. PLOS One 16(8):e0255614, 8/2021. PMCID: PMC8351991.
129. Lu Q, Warmoth K, Chen L, Wu C, Chu Q, **Li Y**, Gallagher MW, Stanton AL, Kagawa-Singer M, Young L, Loh A. A culturally sensitive Joy Luck Academy social support intervention for Chinese American breast cancer survivors: Protocol for a randomized controlled trial. JMIR Research Protocols 10(9):e30950, 9/2021. PMID: 34550088.
130. Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Cabanillas M, Myers J, **Li Y**, Chambers M. Medication related osteonecrosis of the jaw in patients treated concurrently with antiresorptive and anti-angiogenic agents: Systematic review and meta-analysis. Journal of Immunotherapy and Precision Oncology 4(4):196-207, 11/2021.
131. Jones SR, Vidrine DJ, Wetter DW, Shih YCT, Sutton SK, Ramondetta LM, Elting LS, Walker JL, Smith KM, Frank-Pearce SG, **Li Y**, Simmons VN, Vidrine JI. A randomized trial to evaluate the efficacy of a smoking cessation intervention for cervical cancer survivors and women with high-grade cervical dysplasia: Study protocol and design. JMIR Research Protocols 10(12):e34502, 2021. PMID: 34967755.
132. Milbury K, Kroll J, Chen A, Antonoff MB, Snyder S, Higgins H, Yang C, **Li Y**, Bruera E. Pilot randomized controlled trial in women with non-small cell lung cancer to assess the feasibility of delivering group-based psychosocial care via videoconference. Integrative Cancer Therapies 20:15347354211052520, 2021. PMCID: PMC8529304.
133. Singh S, Leticia C. Clemente LC, Parra ER, Tchakarov A, Yang C, **Li Y**, Long JP, Yee C, Lin JS. Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates. OncoImmunology 11(1):e2124678, 9/2022.
134. Lopez G, Eng C, Overman MJ, Ramirez DL, Liu W, Beinhorn C, Sumler SS, Prinsloo S, **Li Y**, Chen M, Bruera E, Cohen L. A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy. Scientific Reports 12:19023, 11/2022.
135. \*Su X, **Li Y**, Müller P, Hsu C-W, Pan H, Do K-A. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling. Pharmaceutical Statistics 21(6):1149-1166, 11/2022. PMID: 35748220.
136. Wang Y, Quesada AE, Zuo Z, Medeiros LJ, Yin CC, Li S, Xu J, Borthakur G, **Li Y**, Yang C, You MJ, Zhang Y, Lin P. The impact of mutation of myelodysplasia-related genes in de novo acute myeloid leukemia carrying NPM1 mutation. Cancers (Basel) 15(1):198, 12/2022. PMCID: PMC9818485.
137. Milbury K, Whisenant M, Weathers SP, Malliaha S, Snyder S, Jackson N, Li J, **Li Y**, Silva RF, Shih YCT, Cohen L. Dyadic versus individual delivery of a yoga program for family caregivers of glioma patients undergoing radiotherapy: Results of a 3-arm randomized controlled trial. Cancer Medicine 12(6):7567-7579, 3/2023. PMCID: PMC10067051.
138. Hart PA, Kudva YC, Yadav Dhiraj, Andersen DK, **Li Y**, Toledo FGS, Wang F, Bellin MD, Bradley D, Brand RE, Cusi K, Fisher W, Mather K, Park WG, Saeed Z, Graham SC, Rinaudo JA, Serrano J, Goodarzi MO. A reduced pancreatic polypeptide response is associated with new onset pancreatogenic diabetes versus type 2 diabetes. Journal of Clinical Endocrinology & Metabolism 108(5):e120-e128, 4/2023. PMID: 36404274.
139. Vidrine JI, Sutton SK, Wetter DW, Shi YCT, Ramondetta LM, Elting LS, Walker JL, Smith KM, Frank-Pearce SG, **Li Y**, Jones SR, Kendzor DE, Vani N. Simmons VN, Vidrine DJ. Efficacy of a smoking cessation intervention for survivors of cervical intraepithelial neoplasia or cervical cancer: A randomized controlled trial. Journal of Clinical Oncology 41(15):2779-2788, 5/2023. PMID: 36921237.
140. Christie AJ, Lopez G, Nguyen CH, Chen M, **Li Y**, Cohen L, Delgado-Guay M. "A pain deep in your soul (being) that is not physical:" Assessing spiritual pain in integrative oncology consultations. Journal of Pain and Symptom Management 65(6):562-569, 6/2023. PMID: 36804423.
141. Deng N, Fahrmann JF, Reyes-Uribe L, Thoman WS, Munsell MF, Dennison JB, Murage E, Wu R, Hawk ET, Thirumurthi S, Lynch PM, Lazard AJ, Jindal S, Chu K, Chelvanambi M, Basen-Engquist K, **Li Y**, Wargo JA, McAllister F, Allison JP, Sharma P, Sinha KM, Hanash S, Gilchrist SC, Vilar E. Exercise training reduces the inflammatory response and promotes intestinal mucosa-associated immunity in Lynch Syndrome patients. Clinical Cancer Research 29(21):4361-4372, 11/2023. PMCID: PMC10618653.
142. Ann-Yi S, Milbury K, Jones M, Necroto V, Whisenant M, **Li Y**, Bruera E. Supportive care for dual caregivers who care for their partner with cancer and their young children. Journal of Pain and Symptom Management 66(5):e603-e609, 11/2023. PMID: 37482225.
143. Lopez G, Chaoul A, Warneke CL, Christie AJ, Powers-James C, Liu W, Narayanan S, Delgado-Guay M, **Li Y**, Bruera E, Cohen L. Self-administered meditation application intervention for cancer patients with psychosocial distress: A pilot study. Integrative Cancer Therapies 22:15347354221148710, 2023. PMCID: PMC98933056.
144. Caswell-Jin JL, Sun L, Munoz D, Lu Y, **Li Y**, Huang H, Hampton JM, Song J, Jayasekera J, Schechter C, Alagoz O, Stout NK, Trentham-Dietz A, Lee SJ, Huang X, Mandelblatt JS, Berry DA, Kurian AW, Plevritis SK. Analysis of Breast Cancer Mortality in the US—1975 to 2019. JAMA 331(3):233-241, 1/2024. PMCID: PMC10792466.
145. \*Yang C, **Li Y**. An extended Bayesian semi-mechanistic dose-finding design in oncology using pharmacokinetic and pharmacodynamic information. Statistics in Medicine 43(4):689-705, 2/2024. PMID: 38110304.
146. Srivastava A, Nogueras Gonzalez GM, Geng Y, Singh J, Myers J, **Li Y**, Chambers MS. Oral toxicities associated with immune checkpoint inhibitors: meta-analyses of clinical trials. Journal of Immunotherapy and Precision Oncology 7(1):24-40, 2/2024. PMCID: PMC10846637.
147. Milbury K, Ann-Yi S, Jones M, **Li Y**, Whisenant M, Yosouf S, Necroto V, Chavez-MacGregor M, Bruera E. Patients with advanced cancer and their spouses parenting minor children: The role of the relationship context in parenting concerns. Psycho-Oncology 33(3):e6310, 3/2024. PMID: 38411282.
148. Liu W, Meyer L, Morse M, **Li Y**, Song J, Engle R, Lopez G, Narayanan S, Soliman PT, Ramondetta L, Bruera E, Cohen L. Dietary magnesium replacement for prevention of hypomagnesemia in ovarian cancer patients receiving carboplatin-based chemotherapy. JCO Oncology Practice 20(4):517-524, 4/2024. PMID: 38301188.
149. Lu Q, Dawkins-Moultin L, Cho D, Tan N, Hopfer S, **Li Y**, Ramondetta L, Xu Y, Lun D, Chen M. A multilevel intervention to promote HPV vaccination among young adults in Texas: Protocol for a randomized controlled trial. BMC Public Health 24(1):1506, 6/2024. PMCID: PMC11151657.
150. Trentham-Dietz A, Chapman CH, Jayasekera J, Lowry KP, Heckman-Stoddard BM, Hampton JM, Caswell-Jin JL, Gangnon RE, Lu Y, Huang H, Stein S, Sun L, Gil Quessep EJ, Yang Y, Lu Y, Song J, Muñoz DF, **Li Y**, Kurian AW, Kerlikowske K, O'Meara ES, Sprague BL, Tosteson ANA, Feuer EJ, Berry D, Plevritis SK, Huang X, de Koning HJ, van Ravesteyn NT, Lee SJ, Alagoz O, Schechter CB, Stout NK, Miglioretti DL, Mandelblatt JS. Collaborative modeling of the benefits and harms of different breast cancer screening strategies with mammography: A decision analysis. JAMA 331(22):1947-1960, 6/2024. PMID: 38687505.
151. Milbury K, Rosenthal D, **Li Y**, Ngo-Huang AT, Mallaiah S, Durrani S, Fuller CD, Lewis C, Bruera E, Cohen L. Dyadic yoga for head and neck cancer patients undergoing chemoradiation and their family caregivers. Journal of Pain and Symptom Management 67(6):490-500, 6/2024. PMID: 38447621.
152. Robertson MC, Swartz MC, Basen-Engquist K, **Li Y**, Jennings K, Thompson D, Baranowski T, Volpi E, Lyons EJ. A social media game to increase physical activity among older adult women: Protocol of a randomized controlled trial to evaluate CHALLENGE. BMC Public Health 24(1):2172, 8/2024. PMCID: PMC11318238.
153. Whisenant M, Weathers S-P, **Li Y**, Aldrich E, Ownby K, Thomas J, Ngo-Huang A, Bruera E, Milbury K. Simulation-based caregiving skills training for family members of high-grade glioma patients. Neuro-Oncology Practice 11(4):432-440, 8/2024.
154. Kim C, **Li Y\***, Xu T, Liao Z. Bayesian nonparametric model for heterogeneous treatment effects with zero-inflated data. Statistics in Medicine 43(30):5968-5982, 12/2024. PMID: 39608809.
155. Villasante-Tezanos A, Kuo Y-F, Kurinec C, **Li Y**, Yu X. A non-parametric approach to predict the recruitment for randomized clinical trials in elderly inpatient setting. BMC Medical Research Methodology 24:189, 2024. PMCID: PMC11363376.
156. Shin-Cho LJ, Dawkins-Moultin L, Choi E, Chen M, Barcenas CH, Roth M, **Li Y**, Lu Q. Feasibility trial of an online expressive writing intervention for young adult cancer survivors. Journal of Adolescent and Young Adult Oncology. In Press.
157. Alagoz O, Caswell-Jin J, de Koning H, Huang H, Huang X, Lee S, **Li Y**, Plevritis S, Sarkar S, Schechter C, Stout N, Trentham-Dietz A, van Ravesteyn N, Lowry K. Mathematical modeling to address questions in breast cancer screening: An overview of the breast cancer models of the Cancer Intervention and Surveillance Modeling Network (CISNET). Journal of Breast Imaging. In Press.
158. Lu Q, Lun D, Dawkins-Moultin L, **Li Y**, Chen M, Giordano SH, Pennebaker JW, Wang C, Young L. Study protocol for Writing to Heal: A culturally based brief expressive writing intervention for Chinese immigrant breast cancer survivors. PLOS One. In Press.
159. Liu W, Zhong B, Wagner RW, Garcia MK, McQuade JL, Huang W, **Li Y**, Nogueras Gonzalez GM, Spano M, Cohen A, Geng Y, Cohen L. Systematic review and meta-analysis of acupuncture for modulation of immune and inflammatory markers in cancer patients. Integrative Cancer Therapies. In Press.

**Invited Articles**

1. **Li Y**. Statistical power analysis for the behavioral sciences. Encyclopedia of Research Design (1st edition; edited by Salkind NJ) 1:1449-1449, 2010.
2. **Li Y**. Power analysis. The SAGE Encyclopedia of Research Design (2nd edition; edited by Frey B) 1:1226-1229, 2022.

**Editorials**

N/A

**Other Articles**

1. Whisenant M, Keathers S-P, **Li Y**, Aldrich E, Ownby K, Thomas J, Ngo-Huang A, Bruera E, Milbury K. A research protocol for a pilot, randomized controlled trial designed to examine the feasibility of a simulation-based caregiving intervention for caregivers of patients with high-grade glioma (under revision). Pilot and Feasibility Studies. Submitted.
2. Yang P, Wei D, Chakraborty S, Nguyen P, Cusimano A, Deng D, Iqbal S, Nelson M, Cui M, Dai J, Gagea M, **Li Y**, Cohen L. Biofield therapy suppresses pancreatic cancer cell growth and metastases in part through the FOXM1 signaling pathway. Cancers. Submitted.
3. Cho D, **Li Y**, Basen-Engquist K, Acquati C, Nguyen NTT, Ma HYH, Pettaway CA, McNeill LH. Couple-based lifestyle intervention for minority prostate cancer survivors: A randomized feasibility trial. Annals of Behavioral Medicine. Submitted.
4. Shin-Cho L, Choi E, Dawkins-Moultin L, Wong CY, Borjas M, Fei F, Xu Y, Chen M, Barcenas C, **Li Y**, Lu Q. Feasibility and acceptability of an online expressive writing intervention for rural breast cancer survivors: A randomized controlled trial. European Journal of Oncology Nursing. Submitted.
5. Toledo FGS, **Li Y**, Wang F, Bellin MD, Brand R, Cusi K, Fisher W, Kudva YC, Park WG, Saeed ZI, Yadav D, Considine RV, Graham SC, Andersen DK, Serrano J, Goodarzi MO, Hart PA. Pancreatic cancer-related diabetes and type 2 diabetes differ in multiple aspects of insulin homeostasis. Diabetologia. Submitted.

**Abstracts**

1. Mazas CA, **Li Y**, Cofta-Woerpel L, Wetter DW, Daza P, Nguyen L, Fouladi RT. Disparities and smoking cessation among Latinos. SRNT Annual Meeting Proceedings(SYM2B):3, 2/2007.
2. Reitzel LR, Vidrine I, **Li Y**, Dolen Mullen P Velasquez MM, Cinciripini MM, Cofta-Woerpel L, Greisinger A, Wetter DW. Influence of subjective social status on vulnerability to postpartum smoking among young pregnant women. SRNT Annual Meeting Proceedings(POS2-84):96, 2/2007.
3. Rowan PJ, Cofta-Woerpel L, Mazas CA, Cinciripini PM, Jones LA, **Li Y**, Ahluwalia JS, Greisinger AJ, Fouladi RT, Wetter DW. Neighborhood social context independently predicts tobacco dependence among African American smokers. SRNT Annual Meeting Proceedings(POS2-135):109, 2/2007.
4. Matin S, Pisters L, **Li Y**, Parker P. Prospective quality of life evaluation in patients undergoing treatment of renal cell carcinoma: interim analysis. American Journal of Kidney Diseases 49(4):B59, 4/2007.
5. Fingeret MC, **Li Y**, Palla SL, Reece GP, Gillenwater AG, Gritz ER. A prospective examination of body image outcomes for patients with oral cancer. Proceedings of the 6th Annual Conference of the American Psychosocial Oncology Society, Charlotte, NC, February 2009, 2/2009.
6. Fingeret MC, Reece G, **Li Y**, Palla S, Gritz ER. Body image concerns among surgically treated oral cancer patients: a potential target for smoking cessation treatment. 2009 Joint Conference of SRNT and SRNT-Europe, 2009.
7. Wetter DW, Businelle MS, Kendzor DE, Mazas CA, Cofta-Woerpel L, Reitzel LR, Vidrine JI, **Li Y**, Costello TJ, Cinciripini PM. Modeling the pathways linking socioeconomic status and smoking relapse: a structural equation modeling approach. Joint Conference of SRNT and SRNT-Europe(SYM 9), 2009.
8. Reitzel LR, Costello TJ, Vidrine JI, **Li Y**, Mullen PD, Velasquez MM, Cinciripini PM, Cofta-Woerpel L, Greisinger A, Wetter DW. Subjective social status is associated with postpartum relapse. Joint Conference of SRNT and SRNT-Europe(SYM 9), 2009.
9. Kendzor DE, Businelle MS, Costello TJ, Castro Y, Reitzel LR, Vidrine JI, **Li Y**, Mullen PD, Velasquez MM, Cinciripini PM, Cofta-Woerpel LM, Wetter DW. Early breastfeeding predicts continued smoking abstinence among women who quit smoking due to pregnancy. Poster presented at the annual meeting of the Society for Research on Nicotine and Tobacco, Baltimore, MD Poster Session 2: Clinical(POS2-12), 2/2010.
10. Businelle MS, Kendzor DE, Reitzel LR, Castro Y, Vidrine JI, **Li Y**, Mullen PD, Velasquez MM, Cinciripini PM, Cofta-Woerpel L, Wetter DW. Pathways linking socioeconomic status and postpartum smoking relapse among women who quit smoking during pregnancy. Poster selected for presentation at the annual meeting of the Society for Research on Nicotine and Tobacco. Baltimore, Maryland Poster Session 2: Clinical(POS2-47), 2/2010.
11. Reitzel LR, Dela Mater R, Cao Y, Cofta-Woerpel L, **Li Y**, Mazas CA, Vidrine JI, Cinciripini PM, Greisinger AJ, Wetter DW. The influence of tobacco retail outlets on smoking cessation during a specific quit attempt (part of The associations of tobacco outlet density, sales, and marketing with neighborhood demographics, and their impact on smoking cessation: New directions for tobacco control policy). Symposium presentation for the Society for Research on Nicotine and Tobacco. Baltimore, MD(SYM 6), 2/2010.
12. Basen-Engquist K, **Li Y**, Carmack CL, Baum G, Hughes DC, Perkins HY, Waters AJ. Ecological Momentary Assessment (EMA) of Morning Self-Efficacy and Positive Outcome Expectations Predicts Daily Exercise in Endometrial Cancer Survivors. 32nd Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine, Washington, DC, 2011.
13. Reitzel LR, Kendzor DE, Castro Y, Cao Y, Mazas CA, Cofta-Woerpel L, **Li Y**, Cinciripini PM, Ahluwalia JS, Wetter DW. Social cohesion affects smoking cessation among African Americans through psychosocial mediators. Paper Session: 16 - Tackling disparities among smokers: The role of race, ethnicity and education. 2011 SRNT Annual Meeting, Toronto, Canada, 2011.
14. Robinson CD, Waters AJ, Reitzel LR, Cinciripini P, **Li Y**, Vidrine JI, Cofta-Woerpel L, Mazas C, Wetter DW. Race and smoking cessation: mediating mechanisms. 2012 Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT), 3/2012.
15. Lahoti S, Reitzel, Cao Y, **Li Y**, Wetter DW, Waters AJ, Vidrine JI. Neighborhood vigilance affects smoking abstinence through health locus of control-chance. Anniversary Biennial Symposium on Minorities, the Medically Underserved & Health Equity: Empowering Communities in the Era of Health Care Reform, 7/2012.
16. Stewart D, Adams C, Correa-Fernandez V, Cao Y, **Li Y**, Waters AJ, Wetter DW, Vidrine JI. Associations between health literacy and smoking. American Public Health Association 140th Annual Meeting & Expo, 10/2012.
17. Basen-Engquist K, Baum G, Perkins HY, Hughes DC, **Li Y**, Carmack CL. Determinants of Exercise-related Self-efficacy & Outcome Expectations in Endometrial Cancer Survivors. 33rd Annual Meeting and Scientific Sessions of the Society of Behavioral Medicine, 2012.
18. Lahoti S, Vidrine JI, Cao Y, Wetter DW, **Li Y**, Waters AJ, Reitzel LR. Health locus of control predicts smoking relapse during a specific quit attempt. Annual Meeting of the Society for Research on Nicotine and Tobacco (oral presentation), 2012.
19. Mayer IA, Abramson VG, Balko JM, Isakoff SJ, Kuba MG, Sanders M, Forero-Torres A, Yap JT, Van Den Abbeele AD, **Li Y**, Arteaga CL, Winer EP. SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC). Journal of Clinical Oncology (suppl; abstr 510) 30, 2012.
20. Adams CE, Chen M, Guo L, Lam CY, Heppner WL, Stewart DW, Cano MA, Correa-Fernández V, Vidrine JI, **Li Y**, Cinciripini PM, Ahluwalia JS, Wetter DW. Associations between trait mindfulness and affective trajectories over the course of smoking cessation treatment. The 2013 Society for Research on Nicotine and Tobacco Annual Meeting, 3/2013.
21. Stewart DW, Correa-Fernandez V, Cano MA, Adams CE, Cao Y, Reitzel LR, **Li Y**, Waters AJ, Wetter DW, Vidrine JI. Social support mediates the relation between health literacy and depression. The Annual Meeting of the Society of Behavioral Medicine, San Francisco, CA, 3/2013.
22. Rogith D, Yusuf RA, Hovick SR, Peterson SK, Burton-Chase AM, **Li Y**, Meric-Bernstam F, Bernstam EV. Attitudes regarding privacy of genomic information in personalized cancer therapy. 2013 ASCO Annual Meeting (#9576), 4/2013.
23. Rafeek AY, Rogith D, Hovick SRA, Peterson SK, Burton-Chase AM, Fellman BM, **Li Y**, McKinney CP, Bernstam EV, Meric-Bernstam F. Racial differences in attitudes toward molecular testing for personalized cancer therapy. 2013 ASCO Annual Meeting (#6566), 4/2013.
24. Castro Y, Heppner W, Vidrine JI, Hernandez M, **Li Y**, Chen M, Cinciripini PM, Wetter DW. Mediators of the association of depression with smoking cessation. Collaborative Perspectives on Addiction, 5/2013.
25. Vidrine JI, Rabius V, Shete S, **Li Y**, Cao Y, Alford MH, Galindo-Talton M, Greisinger A, Harmonson P, Sharp B, Miles Lyndsay, Zbikowski SM, Wetter DW. Ask Advise Connect: Linking smokers in healthcare settings with treatment. Beyond the 5A's: Improving Cessation Interventions Through Strengthened Training, Scottsdale, Arizona:1137-48, 11/2013.
26. Stewart DW, Cano MA, Correa-Fernandez V, Adams CE, **Li Y**, Waters AJ, Wetter DW, Vidrine JI. Lower health literacy predicts smoking relapse among racially/ethnically diverse smokers with low socioeconomic status. Annual meeting of the Society for Research on Nicotine and Tobacco, Seattle, WA, 2/2014.
27. Lee RT, Lopez G, Williams J, Flury J, Spelman A, Onyemeh-Sea A, Spelman A, Fellman B, Garcia K, Chaoul A, Milbury K, **Li Y**, Cohen L. A retrospective analysis of integrative medicine consultations at MD Anderson Cancer Center: Reasons for consultation, symptom burden, quality of life, and satisfaction (poster presentation). J Altern Complement Med 20(5):A122-A122, 5/2014.
28. Lopez G, Lee R, Sumler S-S, Beinhorn C, Chaoul A, Garcia K, Milbury K, Onyemeh-Sea A, Spelman A, Fellman B, **Li Y**, Cohen L. Impact of outpatient massage on symptom expression in cancer patients and caregivers (oral presentation). J Altern Complement Med 20(5):A23-A24, 5/2014.
29. McQuade J, Rosenthal D, Garcia MK, Lee R, **Li Y**, Cohen L. Acupuncture for the management of mucositis pain in patients undergoing radiation for head and neck cancer: a factorial pilot study. An AACR/ASCO Educational Workshop: Methods in Clinical Cancer Research, 7/2014.
30. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies M, Routbort M, Piha-Paul S, Janku F, Ueno N, Hong D, de Groot J, Ravi V, **Li Y**, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills G. Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials. European Journal of Cancer 50(Supplement 6):3, 11/2014.
31. Meric-Bernstam F, Brusco L, Kopetz S, Davies M, Routbort M, Piha-Paul SA, Alvarez R, Khose S, DeGroot J, Ravi V, Janku F, Hong D, **Li Y**, Luthra R, Patel K, Broaddus R, Shaw K, Mendelsohn J, Mills GB. Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials (as a plenary oral presentation). 26th EORTC-NCI-AACR Symposium, 11/2014.
32. Rogith D, Meric-Bernstam F, Yusuf RA, Burton-Chase A, Shelly H, Fellman BM, **Li Y**, Peterson SK, Bernstam EV. Knowledge and Information seeking about personalized breast cancer therapy. 2014 San Antonio Breast Cancer Symposium (poster presentation), 12/2014.
33. Lee RT, Lopez G, Williams J, Flury J, Onyemeh-Sea A, Spelman A, Fellman B, Garcia MK, Chaoul A, Milbury K, **Li Y**, Cohen L. A retrospective analysis of integrative medicine consultations at a major cancer center: reasons for consultation, symptom burden, quality of life, and satisfaction. J Clin Oncol 32(suppl; abstr e17630), 2014.
34. Mayer IA, Abramson VG, Balko JM, Sanders M, Juric D, **Li Y**, Cantley L, Winer EP, Arteaga CL. SU2C phase Ib study of the PI3Kα inhibitor BYL719 with letrozole in ER+/HER2- metastatic breast cancer. J Clin Oncol 32(suppl; abstr 516^):5s, 2014.
35. Mayer IA, Abramson V, Balko J, Sanders M, Juric D, Solit D, **Li Y**, Cantley L, Winer E, Arteaga C. SU2C Phase Ib study of the PI3K-alpha inhibitor BYL719 (alpelisib) with letrozole in ER+/HER2-metastatic breast cancer (plenary presentation). J Clin Oncol(CT232) (#8859), 2015.
36. Correa-Fernández V, Diaz-Toro EC, Reitzel LR, Guo L, Chen M, **Li Y**, Calo WA, Shih YT, Wetter DW. Concurrent Treatment for Smoking Cessation and At-Risk Drinking (oral presentation). 2016 Society for Research on Nicotine & Tobacco Annual Meeting, 3/2016.
37. McNeill LH, Resnicow K, **Li Y**, Nguyen NTT, Roberson CL, Heisler M, Wetter DW. Peer-support motivational interviewing intervention to increase physical activity in sedentary African American women (featured as an excellent submission). The Society of Behavioral Medicine's 37th Annual Meeting and Scientific Sessions, 4/2016.
38. Pena I Jr, Clayman G, Bergeron JM Jr, Grubbs EG, Waguespack SG, Cabanillas M, Dadu R, Hu MI, Fellman BM, **Li Y**, Sturgis EM, Zafereo ME. Predictive factors in patients with sporadic medullary thyroid cancer. The 86th Annual Meeting of the American Thyroid Association, 9/2016.
39. Pena I, Grubbs EG, Kanthasamy KA, Lee JE, Hu MI, Cote GJ, Fellman BM, **Li Y**, Clayman GK, Sturgis EM, Zafereo ME. Prognostic factors in surgical patients with sporadic medullary thyroid cancer. Thyroid 26(S1):P-1-A-129, 9/2016.
40. Lopez G, McQuade JL, Lee RT, Williams J, Spelman A, Fellman B, **Li Y**, Bruera E, Cohen L. Integrative oncology consultation and symptom palliation: Analysis of patient-reported outcomes at a comprehensive cancer center. J Clin Oncol 34(26\_suppl):84, 10/2016. PMID: 28156437.
41. Murthy RK, Song J, Raghavendra AS, **Li Y**, Hsu L, Barcenas CH, Tripathy D, Berry DA, Hortobagyi GN. Proposal for a new breast cancer staging classification: Incorporating clinical and biologic factors. 2016 San Antonio Breast Cancer Symposium, 12/2016.
42. Hoover DS, Wetter DW, Vidrine DJ, Nguyen N, Frank SG, **Li Y**, Waters AJ, Meade CD, Vidrine JI. Enhancing smoking risk communications: The influence of health literacy and message content. The Annual Meeting of the Society of Behavioral Medicine, San Diego, CA, 3/2017.
43. Hoover DS, Knight CJ, Vidrine DJ, Walker JL, Shih T, Wetter DW, Ramondetta LM, **Li Y**, Gillaspy SR, Vidrine JI. Understanding the smoking cessation treatment needs of low socioeconomic status cervical cancer survivors. The Annual Meeting of the Society for Research on Nicotine and Tobacco Research, Florence, Italy, 3/2017.
44. Lopez G\*, Chaoul A\*, Christie AJ, Powers-James C, Liu W, Delgado Guay M, Gomez TI, Warneke CL, **Li Y**, Bruera E, Cohen L. Self-administered meditation application (APP) for cancer patients reporting psychosocial distress: A pilot study. MASCC/ISOO 2021 Annual Meeting on Supportive Care in Cancer, 6/2021.
45. Vidrine JI, Wetter DW, Simmons VN, Sutton SK, Shih YCT, Elting LS, Ramondetta LM, Walker JL, Smith KM, Frank-Pearce SG, **Li Y**, Vidrine DJ. Efficacy of MAPS in facilitating smoking abstinence among cervical cancer survivors: RCT outcomes. The 28th Annual Meeting of the Society for Research on Nicotine and Tobacco, Baltimore, MD, Oral Presentation, 3/2022.
46. Staples C, Jones SR, Vidrine DJ, Wetter DW, Shih YCT, Sutton SK, Ramondetta LM, Elting LS, Walker JL, Smith KM, Frank-Pearce SG, **Li Y**, Simmons VN, Vidrine JI. Recruitment of cervical cancer survivors to a smoking cessation trial: A comparison of in-clinic vs. online approaches. The 28th Annual Meeting of the Society for Research on Nicotine and Tobacco, Baltimore, MD, Poster Presentation, 3/2022.
47. Srivastava A, Nogueras Gonzalez G, Geng Y, Myers J, **Li Y**, Naing A, Chambers MS. Oral toxicities associated with immune checkpoint inhibitors: A meta-analysis of clinical trials. The 2022 AHNS (American Head & Neck Society) Annual Meeting, 4/2022.
48. Hart PA, Andersen DK, **Li Y**, Wang F, Kudva Y, Yadav D, Toledo FGS, Mather K, Saeed Z, Bradley D, Cusi K, Bellin M, Park W, Fisher W, Rinaudo JA, Serrano J, Goodarzi MO. A reduced pancreatic polypeptide response to mixed meal simulation is associated with new onset pancreatogenic diabetes secondary to pancreatic cancer or chronic pancreatitis: Initial results from a multicenter study. Digestive Disease Week (DDW) 2022 (plenary lecture session), 5/2022.
49. Caswell-Jin JL, Sun L, Munoz D, Lu Y, **Li Y**, Huang H, Hampton JM, Song J, Jayasekera J, Schechter C, Alagoz O, Stout NK, Trentham-Dietz A, Lee SJ, Huang X, Mandelblatt JS, Berry DA, Kurian AW, Plevritis SK. Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in US women, 2000-2017. Journal of Clinical Oncology 40(16):Suppl.1008, 6/2022.
50. Toledo FGS, **Li Y**, Wang F, Yadav D, Bellin M, Cusi K, Fisher WE, Kudva YC, Park W, Considine RV, Chari ST, Graham SC, Anderson DK, Rinaudo JA, Serrano J, Goodarzi MO, Hart P. Characterization of metabolic defects in pancreatic cancer–related diabetes and Type 2 diabetes in the DETECT study. Diabetes 72(Supplement\_1):1545-P, 2023.

**Book Chapters**

1. \*Lekdee K, \*Yang C, Ingsrisawang Lily, **Li Y**. A uniform shrinkage prior in spatiotemporal Poisson models for count data. In: Modern Statistical Methods for Health Research. Emerging Topics in Statistics and Biostatistics., First edition. Ed(s) Zhao Y, Chen DG. Springer: Cham, 83-102, 2021. PMID: 978-3-030-72436-8.

**Books (edited and written)**

N/A

**Letters to the Editor**

1. Reitzel LR, Costello TJ, Mazas CA, Vidrine JI, Businelle MS, Kendzor DE, **Li Y**, Cofta-Woerpel L, Wetter DW. Response to Dr. DiFranza's letter. Nicotine Tob Res 11(9):1124-1125, 2009. PMID: 19654235.
2. Barcenas CH, Song J, Murthy RK, Raghavendra AS, **Li Y**, Hsu L, Carlson RW, Tripathy D, Hortobagyi GN. Reply to Letter to Editor: Systematic Bias in Medical Algorithms: To Include or Not Include Discriminatory Information? JCO Clinical Cancer Informatics 6:e2100171, 2022. PMID: 35175860.

**Manuals, Teaching Aids, Other Teaching Publications**

N/A

**Other Publications**

N/A

**EDITORIAL AND REVIEW ACTIVITIES**

**Editor/Service on Editorial Board(s)**

N/A

**Member of Editorial Review Board**

Member of Editorial Board, Journal of Biometrics and Biostatistics, OMICS Publishing Group, 2010-2016

Associate Editor, BMC Medical Research Methodology, BioMed Central, 2011-present

Associate Editor, The American Statistician, 2012-present

Statistical Consultant, Journal of Immunotherapy and Precision Oncology, 2020-present

**Journal Reviewer**

Ad hoc reviewer, Bioinformatics, 2004

Ad hoc reviewer, Biometrics, 2006-present

Ad hoc reviewer, Statistics in Medicine, 2006-present

Ad hoc reviewer, Bayesian Analysis, 2007-present

Ad hoc reviewer, Journal of Biopharmaceutical Statistics, 2007-present

Ad hoc reviewer, Clinical Trials, 2008-present

Ad hoc reviewer, Journal of Psychiatric Research, 2008-present

Ad hoc reviewer, Statistica Sinica, 2008-present

Ad hoc reviewer, Test, 2008-present

Ad hoc reviewer, Computational Statistics and Data Analysis, 2009-present

Ad hoc reviewer, Annals of Applied Statistics, 2010-present

Ad hoc reviewer, Biometrika, 2010-present

Statistical reviewer, BMC Medicine, 2010-present

Statistical reviewer, Circulation: Cardiovascular Quality and Outcome, 2010-present

Ad hoc reviewer, Journal of Statistical Computation and Simulation, 2010-present

Ad hoc reviewer, Scandinavian Journal of Statistics, 2010-present

Ad hoc reviewer, Communications in Statistics - Simulation and Computation, 2011-present

Ad hoc reviewer, Computational Statistics, 2011-present

Ad hoc reviewer, Ethnicity and Health, 2011-present

Ad hoc reviewer, Journal of the American Statistical Association, 2011-present

Ad hoc reviewer, Journal of the Royal Statistical Society, Series B, 2011-present

Ad hoc reviewer, Journal of Probability and Statistics, 2012-present

Ad hoc reviewer, Statistics in Biopharmaceutical Research, 2012-present

Ad hoc reviewer, Statistics in Biosciences, 2012-present

Ad hoc reviewer, Biostatistics, 2013-present

Ad hoc reviewer, Journal of Experimental Education, 2013-present

Ad hoc reviewer, Statistics and Its Interface, 2013-present

Ad hoc reviewer, Biometrical Journal, 2014-present

Ad hoc reviewer, Pharmaceutical Statistics, 2014-present

Ad hoc reviewer, Contemporary Clinical Trials Communications, 2016-present

Ad hoc reviewer, Contemporary Clinical Trials, 2017-present

Ad hoc reviewer, Annals of Internal Medicine, 2020-present

Ad hoc reviewer, Nature Communications, 2020-present

Ad hoc reviewer, JCO Precision Oncology, 2022-present

Ad hoc reviewer, Journal of the National Cancer Institute, 2022-present

Ad hoc reviewer, Nature Medicine, 2023-present

Ad hoc reviewer, Cancer Cell, 2024-present

**Other Editorial and Review Activities**

Reviewer, 2009 23rd Annual Conference on Neural Information Processing Systems (NIPS), reviewed five papers submitted to the conference, 2009

Ad hoc reviewer, A Springer book entitled "Modern Statistical Methods for Health Research", Springer, 2019-2020

Ad hoc reviewer, A Springer book entitled "Precision Medicine: Theory, Methods and Applications", Springer, 2022

**TEACHING**

**Teaching Within Current Institution - GSBS**

**Formal Teaching**

**Courses Taught**

Instructor, Generalized Linear Models and Categorical Data Analysis, GSBS / Rice University, Course Number: STAT 545, Course Hours: 3

Spring, 1/2008-5/2008

Instructor, Generalized Linear Models and Categorical Data Analysis, GSBS / Rice University, Course Number: STAT 545, Course Hours: 3

Spring, 1/2010-5/2010

Instructor, Generalized Linear Models and Categorical Data Analysis, GSBS / Rice University, Course Number: STAT 545, Course Hours: 3

Spring, 1/2014-5/2014

Instructor, Generalized Linear Models and Categorical Data Analysis, GSBS / Rice University, Course Number: STAT 545, Course Hours: 3

Fall, 8/2015-12/2015

Instructor, Modern Nonparametrics, GSBS, Course Number: GS01 1273, Course Hours: 3

Spring, 1/2019-5/2019

Instructor, Generalized Linear Models and Categorical Data Analysis, GSBS / Rice University, Course Number: STAT 545, Course Hours: 3

Fall, 8/2019-12/2019

Instructor, Modern Nonparametrics, GSBS, Course Number: GS01 1273, Course Hours: 3

Spring, 1/2021-5/2021

Instructor, Generalized Linear Models and Categorical Data Analysis, GSBS / Rice University, Course Number: STAT 545/GS01 1233, Course Hours: 3

Fall, 8/2021-12/2021

Instructor, Generalized Linear Models and Categorical Data Analysis, GSBS / Rice University, Course Number: STAT 545 / GS01 1233, Course Hours: 3

Fall, 8/2022-12/2022

Instructor, Modern Nonparametrics, GSBS, Course Number: GS01 1273, Course Hours: 3

Spring, 1/2023-5/2023

**Training Programs**

N/A

**Other Formal Teaching**

N/A

**Supervisory Teaching**

**Committees**

**Advisory Committees**

Member, Biostatistics, GSBS, Chawarat Rotejanaprasert, MS, 12/2008-12/2009

**Supervisory Committees**

Member, Biostatistics, GSBS, Lin Yang, PhD, 8/2009-5/2011

Member, Biostatistics, GSBS, Chunyan Cai, PhD, 5/2011-6/2012

Member, Biostatistics, GSBS, Haitao Pan, PhD, 8/2015-8/2018

Member, Biostatistics, GSBS, Shikun Wang, PhD, 9/2019-5/2022

Member, Biostatistics, GSBS, Yujie Zhao, PhD, 9/2019-7/2022

Member, Biostatistics, GSBS, Mengyi Lu, PhD, 1/2021-present

Member, Biostatistics, GSBS, Feng Tian, PhD, 9/2021-present

**Examining Committees**

Member, PhD Candidacy Examining Committee, Biostatistics, GSBS, Jiong Chen, PhD, 10/2014-12/2014

Member, PhD Candidacy Examining Committee, Biostatistics, GSBS, Xuan Zhu, PhD, 4/2015-6/2015

Member, PhD Candidacy Examining Committee, Biostatistics, GSBS, Heng Zhou, PhD, 6/2016-8/2016

Member, PhD Candidacy Examining Committee, Biostatistics, GSBS, Na Liu, PhD, 5/2019-present

Member, PhD Qualifying Exam Committee, GSBS, Feng Tian, PhD, 10/2022-11/2022

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

N/A

**Graduate Students**

Rotation Advisor, Biostatistics Program, Chao Yang, PhD, 1/2019-3/2019

Rotation Advisor, Biostatistics Program, Yujie Zhao, PhD, 3/2019-5/2019

Research Mentor, Biostatistics Program, GSBS, Chao Yang, PhD, 5/2019-present

Rotation Advisor, Biostatistics Program, Shun Rao, PhD, 5/2022-8/2022

Research Mentor, Biostatistics Program, Shun Rao, PhD, 8/2022-present

**Postdoctoral Research Fellows**

Research Mentor, Beibei Guo, PhD, 11/2010-5/2013

Co-Research Mentor, Biostatistics Program, Xiao Su, PhD, 6/2017-12/2018

**Clinical Residents and Fellows**

N/A

**Other Supervisory Teaching**

N/A

**Teaching Outside Current Institution**

**Formal Teaching**

**Courses Taught**

Instructor, Generalized Linear Models and Categorical Data Analysis, Rice University, Course Number: STAT545, Course Hours: 3

Spring, 1/2012-5/2012

**Training Programs**

N/A

**Other Formal Teaching**

Instructor, Advanced Mathematics, Guangdong University of Technology, Department of Mathematics, Course Hours: 4

6/1994-12/1996

Teaching Assistant, Calculus, University of Toledo, Department of Mathematics, Course Hours: 4

1/1997-8/1998

**Supervisory Teaching**

**Committees**

**Advisory Committees**

N/A

**Supervisory Committees**

External member, Supervisory Committee, Biostatistics, UT School of Public Health, Houston, E Lin, PhD, 1/2014-12/2014

**Examining Committees**

N/A

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

N/A

**Graduate Students**

Thesis Co-Advisor, Statistics, Kasetsart University, Bangkok, Thailand, Krisada Lekdee, PhD, 6/2010-5/2014

Thesis Advisor, Biostatistics, The University of Texas School of Public Health, Houston, Hong Zhang, PhD, 10/2010-5/2013

Thesis Advisor, Biostatistics, The University of Texas School of Public Health, Houston, Xiao Su, PhD, 6/2014-5/2017

Co-Research Mentor, Biostatistics, UT School of Public Health, Yuanliang Yang, PhD, 6/2022-present

Co-Research Mentor, Biostatistics, UT School of Public Health, Bo Zhang, PhD, 11/2022-present

**Postdoctoral Research Fellows**

N/A

**Clinical Residents and Fellows**

N/A

**Other Supervisory Teaching**

N/A

**CONFERENCES AND SYMPOSIA**

**Organization of Conferences/Symposia (Include chairing session)**

International Biometric Society Eastern North American Region (ENAR), Contributed Session of "Survival Analysis II," ENAR Spring Meeting, Austin, TX, Chair, 3/2005

Council of Chapters, American Statistical Association, Invited Poster Session of "Clinical Trial Designs," the Joint Statistical Meetings, Denver, CO, Organizer, 8/2008

Council of Chapters, American Statistical Association (ASA), The Joint Statistical Meetings, Denver, CO, Member of the Conference Program Committee (representing Council of Chapters, ASA), 8/2008

Council of Chapters, the American Statistical Association, Invited Paper Session of "Nonparametric Bayesian Data Analysis," the Joint Statistical Meetings, Denver, CO, Organizer, 8/2008

International Biometric Society Eastern North American Region (ENAR), Invited Session of "Adaptive Designs for Early-Phase Clinical Trials," ENAR Spring Meeting, San Antonio, TX, Chair, 3/2009

International Biometric Society Eastern North American Region (ENAR), Invited Session of "Response-Adaptive Designs for Clinical Trials," ENAR Spring Meeting, San Antonio, TX, Chair, 3/2009

Society for Clinical Trials, Invited session of "New Developments/Emerging Issues in Early Phase Adaptive Clinical Trial Design with Application or Implication in Current or Future Clinical Trials in Asia," Society for Clinical Trials Meeting, Vancouver, British Columbia, Canada, Organizer, 5/2011

The Western North American Region of the International Biometric Society/Institute of Mathematical Statistics, Invited session of "Recent Advances in Missing Data Methods," 2014 WNAR/IMS Conference, Honolulu, HI, Organizer, 6/2014

Section on Bayesian Statistical Science of the American Statistical Association, Invited Session of "Default Bayesian versus Empirical Bayesian Methods and Their Large- and Small-Sample Properties," the Joint Statistical Meetings, Seattle, WA, Organizer, 8/2015

International Chinese Statistical Association (ICSA), Invited session of "Recent Advancement in Adaptive Design of Early Phase Clinical Trials by Accounting for Schedule Effects or Using Other Approaches," ICSA Applied Statistics Symposium, Atlanta, GA, Organizer, 6/2016

International Chinese Statistical Association (ICSA), Invited session of "New methods with large and complex data," ICSA Applied Statistics Symposium, Atlanta, GA, Chair, 6/2016

The European Regional Section of the International Association for Statistical Computing, Invited session of "Recent advancement in biostatistics and biocomputing," 23rd International Conference on Computational Statistics, Iasi, Romania, Organizer, 8/2018

The 3rd International Conference on Econometrics and Statistics, Invited session of "Recent advances in adaptive clinical trial design", Taichung, Taiwan, Organizer and Chair, 6/2019

The iBRIGHT Conference, Invited session of "Clinical trial designs using biomarkers, pharmacokinetics and/or pharmacodynamics", Houston, TX, Organizer, 11/2019

The International Chinese Statistical Association, 2020 ICSA Applied Statistics Symposium, Houston, TX, Member of Both Financial/Business and Student Paper Competition Committees, 12/2020

The International Chinese Statistical Association (ICSA) Applied Statistics Symposium, Invited Session of "Statistical Modeling of COVID-19", Houston, TX, Organizer, 12/2020

The 4th (Virtual) International Conference on Econometrics and Statistics, Invited session of "Nonparametric or default Bayesian methods with applications in medicine", Hong Kong, Hong Kong, Organizer and Chair, 6/2021

The 43rd Society of Clinical Trials (SCT) Annual Meeting, Invited session of "Pharmacokinetics- and/or Pharmacodynamics-Informed Dose-Finding Designs", San Diego, CA, Organizer and Chair, 5/2022

The 5th International Conference on Econometrics and Statistics (EcoSta), Invited session of "Adaptive clinical trial design", Kyoto, Japan, Organizer and Chair, 6/2022

The 24th International Conference on Computational Statistics, Invited session of "Biostatistics and biocomputing", Bologna, Italy, Organizer and Chair, 8/2022

The ICSA 2023 China Conference, Chengdu, Sichuan, China, Scientific Program Committee Member, 7/2023

The ICSA 2023 China Conference, Invited session of "Recent Advancements in Adaptive Clinical Trial Designs", Chengdu, Sichuan, China, Organizer and Chair, 7/2023

The ICSA 2023 China Conference, Invited Session of "Recent Developments in Bayesian Causal Inference", Chengdu, Sichuan, China, Organizer and Chair, 7/2023

The 6th International Conference on Econometrics and Statistics (EcoSta), Invited session of "Early Phase Adaptive Clinical Trial Designs", Tokyo, Japan, Organizer and Chair, 8/2023

The 7th International Conference on Econometrics and Statistics (EcoSta), Invited session of "Statistical and/or Pharmacometric Considerations in Drug Development", Beijing, China, Organizer and Chair, 7/2024

The 8th International Conference on Econometrics and Statistics (EcoSta 2025), Tokyo, Japan, Scientific Program Committee Member, 8/2025

**Presentations at National or International Conferences**

**Invited**

Dose-schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation, Pharmaed Resources' Adaptive Trial Designs Conference: Maximizing the use of Interim Data Analysis to Increase Drug Development Efficiency and Safety, Philadelphia, PA, 9/2007

Center-adjusted inference for a nonparametric Bayesian random effect distribution, Joint Statistical Meetings, Denver, CO, 8/2008

Center-adjusted inference for a nonparametric Bayesian random effect distribution (presented jointly with Peter Mueller), The 2009 International Workshop on Objective Bayes Methodology, The International Society for Bayesian Analysis, Philadelphia, PA, 6/2009

Targeting the PI3K pathway in women's cancers: Some practical examples of the design of early phase Bayesian adaptive trials, The 31st Conference of the ISCB, The International Society for Clinical Biostatistics (ISCB), Montpellier, France, 8/2010

Center-adjusted inference for a nonparametric Bayesian random effect distribution, The 9th International Conference on Health Policy Statistics (ICHPS), Cleveland, OH, 10/2011

Dose-schedule finding in phase I/II clinical trials, The International Chinese Statistical Association 2012 Applied Statistics Symposium, The International Chinese Statistical Association, Boston, MA, 6/2012

Dose-schedule finding in phase I/II clinical trials, The 2013 International Indian Statistical Association Conference, The International Indian Statistical Association, Chennai, India, 1/2013

Bayesian dose finding in phase I/II clinical trials for combination of biologic agents, Third Biennial Workshop on Adaptive Early-Phase Clinical Trial Design, Ann Arbor, MI, 9/2013

Bayesian dose finding in phase I/II clinical trials for combination of biologic agents, Ordered Data Analysis, Models, and Health Research Methods: An International Conference in Honor of H.N. Nagaraja for His 60th Birthday, Richardson, TX, 3/2014

Doubly robust nonparametric multiple imputation for ignorable missing data, The Western North American Region (WNAR)/Institute of Mathematical Statistics (IMS) Conference, Honolulu, HI, 6/2014

Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship, Fourth Biennial Workshop on Adaptive Early-Phase Clinical Trial Design, Charleston, SC, 10/2014

Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering, The International Chinese Statistical Association (ICSA), Joint 24th ICSA Applied Statistics Symposium and 13th Graybill Conference, Fort Collins, CO, 6/2015

A dose-schedule-finding design for phase I/II clinical trials, The International Chinese Statistical Association (ICSA), The 25th ICSA Applied Statistics Symposium, Atlanta, GA, 6/2016

A dose-schedule-finding design for phase I/II clinical trials, 5th Early Phase Adaptive Clinical Trials Workshop, Turin, Italy, 9/2016

Novel Bayesian dose-finding designs accounting for the effects of schedule and method of administration by using pharmacokinetic/pharmacodynamic modeling, The 2nd Symposium on Early Phase Trial Design Methodology, Charlottesville, VA, 4/26/2017

Nonparametric Bayesian IRT models: Some opportunities and challenges, The National Council on Measurement in Education Annual Meeting, San Antonio, TX, 4/29/2017

Novel Bayesian dose-finding designs accounting for the effects of schedule and method of administration by using pharmacokinetic/pharmacodynamic markers, The 40th Annual Midwest Biopharmaceutical Statistics Workshop, Muncie, IN, 5/24/2017

Bayesian dose-finding design for drug combinations based on the trade-offs between partially ordered time to response and toxicity outcomes, 2017 ICSA Applied Statistics Symposium, Chicago, IL, 6/2017

Novel Bayesian dose-finding designs accounting for the effects of schedule and method of administration by using pharmacokinetic/pharmacodynamic modeling, Joint Conference on Biometrics and Biopharmaceutical Statistics, Vienna, Austria, 8/2017

Novel Bayesian dose-finding designs in oncology using pharmacokinetic/pharmacodynamic modeling, The 2nd International Conference on Econometrics and Statistics, Kowloon, Hong Kong, 6/2018

Novel Bayesian dose-finding designs in oncology using pharmacokinetic/pharmacodynamic modeling, The 3rd International Society for Bayesian Analysis - East Asia Chapter (ISBA-EAC) Conference, Seoul, Korea, Republic of, 7/2018

Novel Bayesian dose-finding designs in oncology using pharmacokinetic/pharmacodynamic modeling, IASC-ERS, 23rd International Conference on Computational Statistics, Iasi, Romania, 8/2018

Early phase adaptive clinical trial design, The 7th Workshop on Biostatistics and Bioinformatics, Department of Mathematics and Statistics in the Georgia State University, Atlanta, GA, 5/2019

A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling, The Working Group on Computational and Methodological Statistics, The 3rd International Conference on Econometrics and Statistics, Taichung, Taiwan, 6/2019

A Bayesian semiparametric latent variable approach to causal mediation, The 11th International Chinese Statistical Association (ICSA) Conference, Hangzhou, China, 12/2019

A Bayesian semiparametric latent variable approach to causal mediation, The 2019 International Indian Statistical Association Conference, Mumbai, India, 12/2019

A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling (topic-contributed; virtual), The Joint Statistical Meetings, 8/2020

A uniform shrinkage prior in spatiotemporal Poisson models for count data (virtual), The 4th International Conference on Econometrics and Statistics, Hong Kong, Hong Kong, 6/2021

A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling (canceled due to COVID), The 5th International Workshop on the Statistical Analysis of Multi-outcome Data, Emei, Sichuan, China, 7/2021

A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling, SCT (Society of Clinical Trials) 43rd Annual Meeting, San Diego, CA, 5/2022

A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling (virtual), The 5th International Conference on Econometrics and Statistics (EcoSta), Kyoto, Japan, 6/2022

A uniform shrinkage prior in spatio-temporal Poisson models for count data (virtual), The 24th International Conference on Computational Statistics, Bologna, Italy, 8/2022

A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling, 5th International Conference on PharmScience Research & Development, Las Vegas, NV, 2/2023

A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling, ENAR 2023 Spring Meeting, Nashville, TN, 3/2023

Use of large datasets to facilitate statistical modeling for addressing complex or difficult breast cancer research questions, The 6th Stat4Onc Annual Symposium, Portland, OR, 5/2023

A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling, The ICSA 2023 China Conference, Chengdu, Sichuan, China, 7/2023

A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling (topic-contributed), The Joint Statistical Meetings (JSM), Toronto, Ontario, Canada, 8/2023

A uniform shrinkage prior in spatiotemporal Poisson models for count data, The 6th International Conference on Econometrics and Statistics (EcoSta), Tokyo, Japan, 8/2023

An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information, ENAR 2024 Spring Meeting, Baltimore, MD, 3/2024

An extended Bayesian semi-mechanistic dose-finding design in oncology using pharmacokinetic and pharmacodynamic information, EAC-ISBA Conference 2024, Hong Kong, China, 6/2024

A uniform shrinkage prior in spatiotemporal Poisson models for count data (virtual), The 7th International Conference on Econometrics and Statistics (EcoSta), Beijing, China, 7/2024

An extended Bayesian semi-mechanistic dose-finding design in oncology using pharmacokinetic and pharmacodynamic information, 8th International Early Phase Adaptive Trials Workshop, New York City, NY, 10/2024

**Other, Including Scientific Exhibitions**

Bayesian semiparametric mixed models for longitudinal data (contributed paper), Eastern North American Region (ENAR) Spring Meeting, Washington, DC, 3/2002

Bayesian inference in generalized additive mixed models (contributed paper), Joint Statistical Meetings (JSM), New York City, NY, 8/2002

Bayesian Inference in generalized additive mixed Models with normal random effects (contributed paper), Joint Statistical Meetings (JSM), Ontario, Toronto, Canada, 8/2004

Novel designs for phase I clinical trials based on decision theory (invited presentation; Yuan Ji was presenter; Yisheng Li was co-author), Barnett Educational Services Second Annual Adaptive Design for Clinical Trials: Statistical Methodologies and Applications, London, United Kingdom, 12/2004

Adaptive Bayes designs for dose-finding phase I clinical trials (contributed paper), Eastern North American Region (ENAR) Spring Meeting, International Biometric Society, Austin, TX, 3/1/2005

Novel designs for phase I clinical trials based on decision theory (invited presentation; Yuan Ji was presenter; Yisheng Li was co-author), Barnett Educational Services Third Annual Adaptive Design for Clinical Trials: Statistical Methodologies and Applications, Brussels, Belgium, 5/2005

Dose-finding based on the maximum difference between the probability of response and the probability of toxicity (contributed paper), Eastern North American Region (ENAR) Spring Meeting, Tampa, FL, 3/2006

Practical dose-finding in phase I clinical trials based on toxicity probability intervals (Yuan Ji was presenter; Yisheng Li was co-author), Valencia/ISBA Eighth World Meeting on Bayesian Statistics, Benidorm, Alicante, Spain, 5/2006

Dose-finding in phase I clinical trials based on toxicity probability intervals (Yuan Ji was presenter; Yisheng Li was co-author), XXIII International Biometric Conference, Montreal, Quebec, Canada, 7/2006

Dose-schedule finding in phase I/II clinical trials using Bayesian isotonic transformation (contributed paper), Joint Statistical Meetings, Seattle, WA, 8/2006

Dose finding in phase I clinical trials based on toxicity probability intervals (invited presentation; Presentation given by Yuan Ji, Ph.D. Yisheng Li, Ph.D. is co-author), The 4th Chinese Conference on Oncology (CCO), Tianjin, China, 10/2006

Disparities and smoking cessation among Latinos (Oral presentation given by Carlos Mazas, Ph.D. Yisheng Li, Ph.D. is co-author), Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting, Austin, TX, 2/2007

Neighborhood social context independently predicts tobacco dependence among African American smokers (Poster presentation given by Paul Rowan, Ph.D. Yisheng Li, Ph.D. is co-author), Society for Research on Nicotine and Tobacco (SNRT) Annual Meeting, Austin, TX, 2/2007

The influence of subjective social status on vulnerability to postpartum smoking among young pregnant women (Poster presentation given by Lorraine Reitzel, Ph.D. Yisheng Li, Ph.D. is co-author), Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting, Austin, TX, 2/2007

Bayesian inference in semiparametric mixed models for longitudinal data (poster presentation with a Young Researcher Travel Award), Current and Future Trends in Nonparametrics, Nonparametrics Section, The American Statistical Association, Columbia, SC, 10/2007

Bayesian inference in semiparametric mixed models for longitudinal data (poster presentation with an Early Career Researcher Travel Award), The 9th ISBA world meeting, The International Society for Bayesian Analysis, Hamilton Island, Australia, 7/2008

Bayesian inference in semiparametric mixed models for longitudinal data (poster presentation with a Young Researcher Travel Award), The 11th Annual Winter Workshop on Semiparametric Methodology, University of Florida, Department of Statistics, Gainsville, FL, 1/2009

Bayesian inference in semiparametric mixed models for longitudinal data (won the best [seven] poster presentation award), The International Workshop on Objective Bayesian Methodology, The International Society for Bayesian Analysis, Philadelphia, PA, 6/2009

Center-adjusted inference for a nonparametric Bayesian random effect distribution (topic-contributed paper), Section on Bayesian Statistical Science, The American Statistical Association, Joint Statistical Meetings, Washington, DC, 8/2009

Center-adjusted inference for a nonparametric Bayesian random effect distribution (contributed paper), The 8th International Chinese Statistical Association Conference, Guangzhou, Guangdong, China, 12/2010

Center-adjusted inference for a nonparametric Bayesian random effect distribution (poster), 8th Workshop on Bayesian Nonparametrics, Veracruz, Veracruz, Mexico, 6/2011

Adaptive Bayesian designs for phase I/II clinical trials for drug combinations (poster; Beibei Guo, Ph.D., was presenter; Yisheng Li, Ph.D., was co-author), The Eastern North American Region (ENAR) Spring Meeting, Washington, DC, 4/2012

Doubly robust nonparametric multiple imputation for ignorable missing data (invited presentation; Presenter was Qi Long, Ph.D.; Yisheng Li, Ph.D., was co-author), Eastern North American Region (ENAR) Spring Meeting, Washington, DC, 4/2012

A robust Bayesian approach to assessing average indirect effects in multilevel models, with application to smoking studies (contributed paper), Joint Statistical Meetings, San Diego, CA, 8/2012

Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering (topic-contributed paper), Section on Bayesian Statistical Science of the American Statistical Association, Joint Statistical Meetings, Seattle, WA, 8/2015

A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling (poster), The Population Approach Group in Europe 2019 Meeting, Stockholm, Sweden, 6/2019

A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling, 19th International Conference of Applied Statistics, Koper, Slovenia, 9/2023

An extended Bayesian semi-mechanistic dose-finding design in oncology using pharmacokinetic and pharmacodynamic information (oral contributed presentation), 45th Annual Conference of the International Society for Clinical Biostatistics, Thessaloniki, Greece, 7/2024

**Seminar Invitations from Other Institutions**

Bayesian Inference in Semiparametric Mixed Models for Longitudinal Data, Georgetown University, Department of Biostatistics, Washington, DC, 4/2003

Bayesian Inference in Semiparametric Mixed Models for Longitudinal Data, Indiana University Purdue University, Division of Biostatistics, School of Medicine, Indianapolis, IL, 5/2003

Bayesian Inference in Semiparametric Mixed Models for Longitudinal Data, Bristol-Myers Squibb Company, Department of Biostatistics, Wallingford, CT, 6/2003

Bayesian Inference in Semiparametric Mixed Models for Longitudinal Data, University of Illinois at Chicago, Division of Epidemiology and Biostatistics, School of Public Health, Chicago, IL, 6/2003

Bayesian Inference in generalized additive mixed models, University of Texas School of Public Health, Division of Biostatistics, Houston, TX, 2/2004

Bayesian inference in semiparametric mixed models for longitudinal data, Northeastern University, Department of Health Sciences, Boston, MA, 6/2010

Center-adjusted inference for a nonparametric Bayesian random effect distribution, University of Hong Kong, Department of Statistics and Actuarial Science, Hong Kong, China, 6/2010

Seven seminars were given: 1) Bayesian methodology: An overview; 2) Dirichlet processes: A gentle tutorial; 3) Bayesian inference in semiparametric mixed models for longitudinal data; 4) Center-adjusted inference for a nonparametric Bayesian random effect distribution; 5) Dose-schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation; 6) Adaptive design to identify treatments for biomarker subtypes; 7) Stand up to cancer (SU2C): Targeting the PI3K pathway in women's cancers, Kasetsart University, Department of Statistics, Bangkok, Bang Khen, Thailand, 6/2010

Bayesian inference in semiparametric mixed models for longitudinal data, University of Rochester, Department of Biostatistics and Computational Biology, Rochester, NY, 7/2010

Center-adjusted inference for a nonparametric Bayesian random effect distribution, The University of Texas School of Public Health, Division of Biostatistics, Houston, TX, 7/2010

Bayesian inference in semiparametric mixed models for longitudinal data, South China Agricultural University, Department of Applied Mathematics, Guangzhou, Guangdong, China, 12/2010

Dose-schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation, Fudan University, Division of Biostatistics, Shanghai, China, 12/2010

Bayesian inference in semiparametric mixed models for longitudinal data, University of Louisville, Department of Bioinformatics and Biostatistics, Louisville, KY, 4/2012

Early phase adaptive designs with a few real trial examples, San Diego Chapter of the American Statistical Association, San Diego, CA, 4/2012

Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering, The Fourth Military Medical University, Section of Biostatistics in the Department of Preventive Medicine, Xi'an, Shaanxi, China, 3/31/2014

Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering, Center for Clinical and Translational Sciences at the University of Texas Health Science Center at Houston, Biostatistics, Epidemiology, and Research Design Core, Houston, TX, 8/2015

**Lectureships and Visiting Professorships**

Visiting Assistant Professor, Rice University, Department of Statistics, Houston, TX, 2008

Visiting Assistant Professor, Rice University, Department of Statistics, Houston, TX, 2010

Visiting Associate Professor, Rice University, Department of Statistics, Houston, TX, 2014

**Other Presentations at State and Local Conferences**

N/A

**PROFESSIONAL MEMBERSHIPS/ACTIVITIES**

**Professional Society Activities, with Offices Held**

**National and International**

Student Activity Committee, Department of Biostatistics, University of Michigan, Ann Arbor, MI

Member, 2000-2001

American Statistical Association

Member, 2004-present

President-Elect, Houston Area Chapter, 2005-2006

President, Houston Area Chapter, 2006-2007

Past President, Houston Area Chapter, 2007-2008

Program Committee Member, Joint Statistical Meetings, 2008

Eastern North American Region (ENAR), International Biometric Society

Member, 2004-present

International Society for Bayesian Analysis

Member, 2008-present

Society for Clinical Trials

Member, 2008-present

Royal Statistical Society, United Kingdom

Fellow, 2015-present

International Society for Clinical Biostatistics, Greece

Member, 1/2024-present

**Local/State**

N/A

**UNIQUE ACTIVITIES**

N/A

**DATE OF LAST CV UPDATE**

12/16/2024